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Abstract
Dose-finding trials are a form of clinical data collection process in which the primary
objective is to estimate an optimum dose of an investigational new drug (IND). Based
on the purpose of a dose-finding trial the optimum dose can be either a maximum tol-
erated dose (MTD) or an optimum biological dose (OBD) or an MTD combination of
combined drugs. This thesis develops three novel dose-finding design methodologies
which are reminiscent of the well-known continual reassessment method (CRM).
The first design methodology incorporates adverse event relatedness into the CRM.
It selects the targeted dose efficiently and gathers more information about adverse
events which have uncertain relatedness to the IND. This design methodology demon-
strates that adverse event relatedness is important for improved MTD estimation.
The second design methodology is based on toxicity and efficacy outcomes which
estimate the toxicity and efficacy marginal probabilities separately. It also estimates
the toxicity-efficacy interaction at each dose level using cross-ratios. It uses the
Expectation-Maximisation algorithm to predict the missing efficacy outcomes. Both
ordinal and binary versions of this design have good operating characteristics in se-
lecting the appropriate OBD.
The third design methodology is developed for phase I drug combination trials.
This design methodology uses two-parameter logistic models to estimate the latent
marginal toxicity effects of each drug and the Plackett distribution to estimate the
drug-drug interaction effect. Binary and ordinal versions of the design show fair
operating characteristics in selecting the appropriate MTD combinations.
All design methodologies presented in this thesis are pragmatic. They use logistic
models, incorporate clinicians’ prior knowledge efficiently, and prematurely stop a
v
trial for safety or futility reasons. Designing actual dose-finding trials using these
methodologies will minimise operational difficulties, improve efficiency of dose esti-
mation, and be flexible to stop early.
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Chapter 1
Introduction
The development of an investigational new drug (IND) is complex during its early tests
in human subjects. The complexities originate in selecting a dose to be administered
in human subjects. It is desirable to test a dose of an IND first in humans because it has
the potential to cure a disease, meanwhile it is undesirable because it is highly toxic.
If the response to a dose is defined in probability terms, then an optimum dose can
be estimated using statistical models. However, establishing the scientific experiment,
namely clinical trial design, demands a mixture of statistical and clinical reasoning.
Although several dose-finding clinical trial design methodologies exist, the widely
known continual reassessment method (CRM) is the only pragmatic design methodol-
ogy which balances both statistical and clinical perspectives. This thesis presents new
dose-finding design methodologies which extends the CRM design methodology.
1.1 Dose-Finding Designs
Dose-finding designs are a form of clinical trial treatment regime, with the primary
objective of estimating an optimum dose. The optimum dose is an ideal dose which
satisfies certain clinical conditions. If toxicity is the primary measure for an IND,
then the optimum dose is the maximum tolerated dose (MTD). The MTD is a dose
with toxicity probability closest to a pre-specified target probability of toxicity. If
a drug combination is concurrently tested for joint toxic effects then the optimum
dose is an MTD combination with joint toxicity probability closest to a target toxicity
probability. In bivariate dose-finding designs, where both toxicity and efficacy are
1
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primary measures, the optimum dose is the so called optimum biological dose (OBD).
An OBD is a dose with maximum efficacy provided its toxicity probability is below
a given cut-off. The definition of an optimum dose is subject to change for different
dose-finding design methodologies. Three novel dose-finding design methodologies
with different definitions of optimum doses are developed in this thesis.
Designs based only on the dose-toxicity relationship are mandatory for drugs in
which harmful adverse events are expected. A therapeutic dose of harmful drugs
is expected to cause a significant amount of toxicity to cure the disease. Also, a
severe toxicity can cause harm to a patient. A sensible way to estimate an MTD of
a harmful IND is to measure toxicity on a probability scale, define the acceptable
amount of toxicity as the target toxicity probability, and treat patients closer to the
target toxicity probability. However, an observed toxicity may not be caused by the
IND. It may be due to an underlying disease, environmental or toxic factors, or other
drug or therapy. Generally, the toxicity relationship to the IND is not incorporated
into the design methodology, which leads to flawed MTD estimation.
Designs based on both dose-toxicity and dose-efficacy relationships are known as
bivariate dose-finding designs. Bivariate dose-finding design methodologies generally
do not assume a flexible parametric model for the unknown dose-efficacy relationship.
This relationship can be monotone increasing, monotone decreasing, or unimodal.
These three relationships should be accounted for in a flexible bivariate dose-finding
design because OBD estimation may heavily depend on the features of the dose-
efficacy function.
Bivariate dose-finding designs jointly evaluate both toxicity and efficacy. The de-
pendency structure between toxicity and efficacy plays a key role in dose estimation. A
flexible parametric structure which accounts for marginal dose-toxicity, dose-efficacy
relationships, and the toxicity-efficacy interaction is necessary. Such a parametric
structure avoids the restrictive assumption of a single underlying density function.
Bivariate dose-finding trials suffer from late-onset efficacy outcomes because ef-
ficacy outcomes generally take a longer time to observe than toxicity outcomes. To
enrol patients when they become available, once the toxicity endpoint is met, the late-
onset efficacy outcomes need to be predicted. A reasonable prediction of the late
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onset efficacy outcome would use the available toxicity outcome and the dependency
structure between toxicity and efficacy. Once an efficacy outcome becomes available
the predicted outcome should be replaced by the observed outcome. Currently, there
is no versatile bivariate dose-finding design methodology. Versatile means a flexible
model for the dose-efficacy relationship and a parameter to measure the interaction
effect with a reasonable statistical technique to predict the late-onset efficacy outcome.
Sometimes more than one IND is developed concurrently to optimise the treatment
effect or simultaneously target multiple diseases. The safety of a combined drug
is assessed first if this type of dose-finding trial, namely a drug combination trial,
is set to jointly evaluate the toxicity effect of combined drugs. In this design, the
effects of dose combinations are spread over a multidimensional space which includes
the interaction between the INDs. Some drug-combination design methodologies
partially order the dose combinations to be administered. Such a design methodology
simplifies the space of the effects of the dose combinations into a single dimension.
However, generally such an ordering will not accurately estimate a joint optimal dose
combination because it fails to account for the drug-drug interaction.
Identifying the interaction effect between drugs is rather complicated. Once mul-
tiple drugs are administered to a patient, a resulting adverse event is due to one of
the individual drugs or possibly the joint effect of all or some drugs. Under such
circumstances the individual effect of each drug cannot be observed. However, simul-
taneous modelling of the marginal effect of each drug and the interaction effect of all
administered drugs should accurately estimate an MTD combination.
An attractive feature of all dose-finding designs is that they are sequential by
nature. Sequentially increasing doses are administered to cohorts of patients and
a trial terminates when predefined clinical outcomes are satisfied. The sequential
nature of these designs largely removes major statistical concerns about sample size,
cohort size, power and type I error of a design methodology. Statistical concerns of
dose-finding design methodologies are the accuracy of selecting a dose for a cohort
of patients and the global optimisation of a dose level using the true dose-response
relationship. A negative aspect of the sequential procedure is, it does not provide ac-
curate estimation of the optimum dose unless a parametric dose-response relationship
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is assumed. A sequential dose-finding design methodology that tends to estimate an
unbiased optimum dose is the so called CRM.
1.2 Continual Reassessment Method
O’Quigley et al. (1990) first proposed the CRM, primarily to estimate the MTD.
The CRM assumes a one-parameter model for the dose-toxicity relationship and an
uninformative prior distribution is assumed for the model parameter. It specifies
clinicians’ expert knowledge as the toxicity probability for each test dose level. The
toxicity probability of each dose level is continually reassessed, based on observed
toxicity outcomes, during every sequence of the trial. At the current sequence, a dose
level which has the estimated toxicity probability closer to the pre-specified target
toxicity probability is administered to the following cohort of patients. Finally, the
dose level selected at the end of a trial is determined as the MTD. The CRM has
generated a huge literature over the last two decades. Several modifications have been
made to adopt this methodology under different clinical circumstances. However, the
CRM can be further extended to incorporate adverse event relatedness of the IND,
ordinal toxicity and efficacy outcomes with an interaction effect, and ordinal toxicity
outcomes with drug-drug interaction.
The idea of prior beliefs used in the original CRM has been changed by later
authors. The Clinicians’ expert belief was expressed as the toxicity probability at
each dose level. Specifying an expected toxicity probability at each dose level has
been replaced by later developments. These toxicity probabilities are neither down
weighted nor diminished as a trial progresses in the original CRM. Consequently the
design methodology is heavily influenced by expert belief. In addition, a Normal
distribution with mean zero and an arbitrarily chosen standard deviation is used as a
prior distribution for the dose-toxicity model parameter. To overcome all these issues,
Piantadosi et al. (1998) introduced a pragmatic CRM in which prior toxicity data at
at least two dose levels are incorporated into the design, and the prior data are down
weighted as the trial progresses. Designs developed in this thesis use prior information
of a low and high dose level with prior data weights.
The true dose-response relationship is unknown, and therefore, the CRM uses a
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statistical model to describe it. Although this parametric model assumption is crucial,
the choice of a statistical model has been overlooked as a concern of the CRM.
The first proposal, the original, CRM uses a one parameter model because the small
number of patients is inadequate in estimating more than a single parameter. However,
a single parameter model is inadequate in representing the important nuances of real
data. Furthermore, it cannot behave, qualitatively, in the correct way. A model with
more than a single parameter is necessary to substantially contribute to the available
information when a few responses are observed.
This thesis uses multi-parameter logistic models to describe the dose-response
relationships. The true dose-response relationship has a certain biological form. The
form is either complete or partial imitations of the sigmoid curve. Logistic models
with appropriate parameterisations fulfil the biological form of the dose-response
relationship. Throughout this thesis, model parameters are estimated by maximising
the appropriate likelihood.
This thesis identifies major problems in three different dose-finding design method-
ologies. Firstly, no design methodologies in practice incorporate adverse event relat-
edness. If adverse event relatedness is incorporated into designs based only on the
dose-toxicity relationship then the number of patients assigned to high toxic dose lev-
els may be reduced. Furthermore, the incorporated adverse event relatedness will lead
to better MTD estimation. Secondly, bivariate dose-finding designs without severity of
toxicity and progress of efficacy information lead to poor OBD estimation. Late-onset
efficacy outcomes are unavoidable in bivariate clinical settings. A bivariate dose-
finding design methodology should predict the efficacy outcomes using the available
toxicity information and its interaction with efficacy data. Finally, drug-combination
trials do not incorporate the severity of toxicity information. The joint effects of
the combined drugs are not decomposed into marginal effects of each drug and the
interaction effect of combined drugs. Such decomposition is necessary to accurately
estimate the toxicity surface of the dose combinations.
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1.3 Objectives
The overall objective of this thesis is to develop novel dose-finding design method-
ologies that can be used to estimate an optimum dose accurately. In particular, to
extend the renowned continual reassessment method under three different optimum
dose estimation strategies given below
• To incorporate adverse event relatedness into the CRM. The specific aim is
to improve MTD estimation by incorporating the uncertainty of the observed
toxicities (if it was related or not to the IND) into the pragmatic CRM.
• To develop a novel bivariate dose-finding design methodology which can esti-
mate an accurate OBD. The global aim is to handle late-onset efficacy outcome
while developing a flexible model for dose-efficacy relationship. Also, to effec-
tively estimate the toxicity-efficacy interaction.
• To accurately estimate an MTD drug combination. Specifically, to estimate
the joint toxicity effect of each test dose combination. Also, to incorporate
severity of toxicity information into the dose-finding design methodology using
combined drugs.
1.4 Thesis Outline
This thesis presents three novel dose-finding design methodologies. Chapter 2
reviews the literature. It begins by introducing the dose-finding design methodologies
and the renowned CRM. This chapter then outlines major modifications made to the
original CRM. This thesis focuses on extending the pragmatic version of the CRM.
Therefore, chapter 2 explains the pragmatic CRM in detail. A number of issues
associated with the pragmatic CRM are outlined.
Chapter 3 incorporates adverse event relatedness into the pragmatic CRM. This
chapter categorises the observed adverse events into two: ‘doubtfully’ or ‘possibly’
and ‘probably’ or ‘definitely’ related to the IND. The maximum estimated toxicity
probability of these two adverse event relatedness categories is used to estimate the
MTD. Two simulation studies presented in this chapter show that the novel design
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methodology is effective in estimating the MTD.
Chapter 4 presents a novel bivariate dose-finding design methodology. This method-
ology uses the global cross-ratio to measure the association between toxicity and
efficacy. This design methodology accounts for late onset efficacy outcomes. It also
incorporates severity of toxicity and progress rate of efficacy information into the
design methodology. Two simulation studies presented in this chapter show that the
design methodology is efficient in estimating an OBD.
Chapter 5 extends the pragmatic CRM to identify the safety profile of a drug
combination. This chapter presents the basic form of a novel design methodology
using two drugs. The global cross-ratio is used in this chapter to capture the drug-
drug interaction effect. The severity of toxicity information is taken into account in
the drug-combination design methodology. Two simulations studies presented in this
chapter show that the novel design methodology has fair operating characteristics in
selecting the appropriate MTD combinations.
To conclude, Chapter 6 summarises the major contributions of this thesis and
outlines possible future research.
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Chapter 2
Continual Reassessment Method in Practice -
A Literature Review
Synopsis
This chapter critically examines the renowned continual reassessment method
(CRM) and its major modifications. It describes the three important modifications
made to the original CRM; time-to-event CRM, bivariate CRM and the pragmatic
CRM. This chapter emphasis on the pragmatic version of the CRM and its superiority
in incorporating prior knowledge into the design methodology. In addition, this chap-
ter reviews computer software programs primarily associated with the CRM method-
ology. This is because statistical software programs are the key link between the
CRM designs and their applications in practice. However, general statistical software
programs do not have specific menu options to implement the CRM algorithm. The
pragmatic version of the CRM described in this chapter is further extended throughout
this thesis.
2.1 Dose-Finding Design Methodologies
A dose-finding clinical trial is a scientific experiment which is conducted in the
early stages of the drug development process. The primary objective of this exper-
iment is to estimate an optimum dose. An optimum dose is the ideal dose which
satisfies some pre-specified clinical goals. The clinical goal of an optimum dose can
9
10 CHAPTER 2. LITERATURE REVIEW
be used to categorise dose-finding trials into three main types. If the objective is to
find a maximum tolerated dose (MTD), that is, a dose with tolerable toxicity, then
toxicity is the primary measure of the dose-finding trial. This type of univariate trial
is sometimes known as a phase I trial or first in man trial (Storer, 1989). Finding an
optimum biological dose (OBD), that is, a dose with highest efficacy and tolerable
toxicity, is the objective of some dose-finding trials. This type of trial is known
as a bivariate or phase I-II dose-finding trial (Zohar and Chevret, 2007). If two or
more drugs are concurrently developed in combination then the first critical step is
to identify an MTD combination (Hamberg and Verweij, 2009). For each type of
dose-finding trial: univariate or phase I, bivariate or phase I-II, and phase I drug
combination, this thesis develops a novel dose-finding design methodology.
Dose-finding design methodologies demand a mixture of clinical and statistical
concepts. This is because the drug under development is lethal for human beings.
Some dose-finding design methodologies are purely based on clinical concepts only.
These methodologies, namely, conventional dose-finding designs, observe an opti-
mum dose from the data by setting-up some rules. There are several varieties of
conventional dose-finding design methodologies, among them, up-and-down designs
(Ivanova and Flournoy, 2006), ‘3+3’ designs (Ivanova, 2006), and accelerated titration
designs (Simon et al., 1997) are most commonly mentioned in the literature. These
designs have no statistical basis (Rosenberger and Haines, 2002). They do not define
the dose-response relationship in probability terms and, therefore, there is no pre-
specified target probability for the optimum dose level (Storer, 2006). Furthermore,
conventional designs do not incorporate all available data in observing an optimum
dose, meaning these designs are memoryless. For these reasons this thesis ignores
conventional designs and rather focuses on dose-finding design methodologies based
on sound statistical procedures.
An estimated optimum dose of a dose-finding trial will be passed for further
testings which implies an accurate determination of the optimum dose is crucial.
If a dose below the true optimum dose is passed for further testing then the drug
will be identified as ineffective. This may lead to a costly failure in the entire drug
development process. If a dose above the true optimum dose is passed for further
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experimentation then the patients will receive a dose with a severe or life-threatening
adverse event with high probability. Identifying the exact optimum dose is the major
problem of dose-finding design methodology. Accuracy of the optimum dose esti-
mation entirely depends on the methodology used for setting the clinical trial. A
dose-finding design methodology based on essential statistical concept with sufficient
clinical reasoning would estimate an accurate optimum dose.
Dose-finding designs are conducted with small sample sizes because of ethical
concerns about exposing patients to risks that do not outweigh the benefits. These
designs are sequential by nature, and therefore, sample size is not a major statistical
concern. Sample size which is typically small is an outcome of using a sequential
design. To make a decision about the optimum dose, sufficient information of the true
dose-response relationship of an IND is obtained by sequentially enrolling a small
number of patients to test dose levels. However, a small sample size should not be a
logical reason for ignoring statistical techniques in the design methodology. A small
sample yields a relatively small amount of information from the data. Therefore, a
parametric assumption on the dose-response relationship is indispensable.
The attractive sequential feature allows updating the statistical model parameters
between patient enrolments. Within each sequence, decisions can be made by opti-
mising a utility function. Furthermore, estimated probabilities from a statistical model
can be used to prematurely stop a trial for safety or futility reasons. However, the
sequential feature tends to estimate a biased optimum dose. A design that estimates
an unbiased optimum dose is the widely known CRM (Piantadosi, 2005).
O’Quigley et al. (1990) first proposed a model-based design based on Bayesian
statistical methods and named it as the continual reassessment method (CRM). The
CRM incorporates all previously available data to select a dose for new patients. The
CRM has been proven to be robust in estimating the MTD (Cheung, 2011, O’Quigley
and Conaway, 2010, O’Quigley and Zoharb, 2010). However, Rogatko et al. (2007)
show that the CRM has not been widely used in practice. To ensure the design is
applicable to different circumstances, several modifications have been made to the
CRM. These variations can be confused without proper understanding with the theory
behind the CRM. Furthermore, in implementing the CRM, the calculation of the
12 CHAPTER 2. LITERATURE REVIEW
posterior probability of toxicity for each dose level requires numerical integration.
The CRM is problematic in practice due to its computational difficulties (Iasonosa
and O’Quigley, 2011).
Several model-based designs have been proposed since the invention of the CRM.
These include the Bayesian decision-theoretic design by Whitehead and Brunier (1995),
escalation with overdose control by Babb et al. (1998), isotonic design by Leung and
Wang (2001), and Bayesian c-optimal design by Haines et al. (2003). However, these
designs are rarely used in practice. The CRM has generated extensive literature, much
of which proves CRM to be reliable in estimating MTD. This is particularly significant
for the adoption of the CRM in practical circumstances. For these reasons dose-finding
design methodologies developed in this thesis are reminiscent of the CRM. Section 2.2
describes the CRM and its properties.
2.2 Continual Reassessment Method
The CRM was first developed for cancer phase I clinical trials. This method de-
termines the MTD closest to a target toxicity probability. The CRM assumes toxicity
increases with increasing dose and the doses are tested with increasing prior toxicity
probability.
Suppose a finite set of doses is selected and the best guess of the probability of
toxicity for each dose is specified. The original CRM suggests selecting the first
dose arbitrarily. Based on the binary toxicity outcome (dose limiting toxicity or
not), the CRM calculates the posterior probability of toxicity for each dose. The next
patient is treated with the dose that has the posterior probability closest to the target
probability of toxicity. Based on the observed patient outcomes, the CRM recalculates
the posterior probability of toxicity for each dose. The process iterates until all patients
are treated. The global MTD is the dose closest to the target probability of toxicity,
based on all patient outcomes.
Let N be the total number of patients selected for the trial with K dose levels
recommended from pre-clinical studies. The CRM requires specifying a skeleton,
that is, the best guess of the probability of toxicity for each dose level. Let Pt1 <
· · · < PtK be the skeleton. Suppose a dose-limiting toxicity (DLT) is observed after
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administering the dose di (i = 1 . . . K). The one-parameter dose-response model used
in the CRM is given by
Pr(T = 1|di) = ξt(di, βt); βt ∈ (0,∞), (2.1)
where {T = 1} means dose limiting toxicity and ξt is a monotonic function. The
model parameter βt is unknown and is assumed to follow a prior distribution p(βt).
The CRM requires dose levels to be ordered with increasing prior toxicity prob-
ability. The dose levels (d1, . . . , dK) in the CRM and the actual doses administrated
(e.g., 0.8 mg/Kg) are different. The dose levels d1, . . . , dK are calculated using back-
ward substitution given by
Pti = ξt(di,Ep(βt)[βt]), i = 1, . . . , K, (2.2)
where Pti is the prior probability of toxicity for the dose di and Ep(βt)[βt] is the prior
mean of βt. The exact fit of the dose-response model ξt over the skeleton is ensured by
equation (2.2). Therefore, a different choice of ξt will produce different dose levels.
The functional form of the dose-response model ξt plays a key role in designing the
CRM. The power model (2.3) below and the one parameter logistic model (2.4) below
are the most commonly used models.
ξt(di, βt) = d
exp(βt)
i , (2.3)
ξt(di, βt) =
exp(α0 + βtdi)
1 + exp(α0 + βtdi)
, (2.4)
where α0 is a fixed constant. The choice of α0 = 3 is widely used in the literature.
This choice is based on Chevret (1993), who claims that the choice of α0 = 3 performs
better than the power model, because of the skeleton used in her simulation study. The
choice of α0 (intercept of the logistic model), however, should not be blindly followed.
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Suppose a cohort of ni patients is assigned to dose level di and yi patients experi-
ence a DLT. The likelihood function for observations y1:K is given by
p(y1:K |βt, n1:K , d1:K) =
K∏
i=1
[ξt(di, βt)]
yi [1− ξt(di, βt)]ni−yi . (2.5)
Let the prior information for βt be given by a prior distribution p(βt). The posterior
distribution of βt is given by
p(βt|y1:K , n1:K , d1:K) ∝ p(βt)p(y1:K |βt, n1:K , d1:K) (2.6)
The expected posterior probability of toxicity for each dose is given by,
ξt(di) =
∫
ξt(di, βt)p(βt|y1:K , n1:K , d1:K) dβt, i = 1, . . . , K. (2.7)
Let φt be the target toxicity probability, the next cohort of patients will be treated
at dose dl ∈ (d1, . . . , dK) if and only if
|ξt(dl)− φt| < |ξt(dj)− φt|, j = 1, . . . , K, dl 6= dj. (2.8)
That is, the dose level selected for the next cohort of patient has the posterior proba-
bility of toxicity closest to the target probability of toxicity.
A Computer Program for the Original CRM
A computer software program is necessary to design a dose-finding trial using the
original CRM described above. The freeware CRM Version 1.0 uses a general com-
mand line implementation to design clinical trials using the CRM (Venier et al., 1999).
This software program was developed at the M.D. Anderson Cancer Centre, the last
version, 1.0, was released on February 19, 1999. Ad hoc rules to the CRM proposed
by Goodman et al. (1995) are implemented in this software program.
This software program was developed in Fortran 77, a pre-compiled win32 file
is available at the software web-site. Instead of installing the program, the user
must download the file ‘CRM V1.0.tar.gz’ and extract it. Since it is a pre-compiled
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program, double-clicking on the executable file ‘crm.exe’ will run the program. A 69
page user manual (Crm.pdf) which describes command lines of this software program
is well organised and easy-to-read.
CRM Version 1.0 Features
The main feature of CRM Version 1.0 is the option to simulate the ‘3+3’ rule-based
design simultaneously with CRM simulations. Therefore, the operating characteris-
tics of these two designs can be compared. Three dose-response model choices are
implemented in this software program. The first choice is the power model (2.3)
with a N(0, 1.342) prior distribution for βt. The second and third choices are the
one parameter logistic model (2.4) with α0 = 3. An exponential prior distribution
(exp(−βt); βt > 0) is used with the second choice, whereas a uniform prior distribu-
tion on the interval [0,3] is used in the third choice. The CRM Version 1.0 includes
clear recommendations while conducting the trial and warning messages regarding
violations of the CRM protocol.
The ‘LOOK AHEAD’ option is an additional feature implemented in this software
program. If this option is selected, dose levels for the next cohort of patients will
be pre-calculated before the toxicity of the current cohort is observed. The CRM
version 1.0 offers two stopping criteria for the design. Users must provide either the
maximum number of patients in the trial or the minimum number of patients who
will be treated at the MTD. The minimum number of patients in the trial can also be
specified. However, if a value for the minimum number of patients is given, the trial
cannot be terminated before reaching this value.
CRM Version 1.0 Limitations
This software program is not user-friendly and a few features are missing. Firstly,
the user has to type commands in a DOS command window (Figure 2.1). Secondly,
no built-in graphical display means the user has to plot the posterior probability of
toxicity in another software program. Thirdly, the ‘LOOK AHEAD’ option may skip
dose levels and recommend a toxic dose as the current cohort toxicity response is yet
unknown. Finally, the average number of toxicity and average number of patients
treated in each scenario are provided in the output, but standard deviations of these
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estimations are not provided. Appendix A provides a simulation study using this
software program.
Figure 2.1: CRM Version 1.0 Window
2.3 Modifications Made to the Original CRM
The operating characteristics of a design rely on starting dose, stopping rule,
cohort size, sample size, target toxicity probability and the number of test dose levels.
Criticisms of CRM include: the starting dose is too toxic, dose escalation by more
than one dose level may be harmful and the trial period is long due to the cohort size
of one. Goodman et al. (1995) proposes ad hoc rules to the CRM, which starts the trial
always at the lowest dose level and does not allow dose escalation by more than one
dose level. The trial is stopped when a predefined number of patients are treated at the
MTD. Statistical properties of these ad hoc rules are not verified, but seem harmless
to the CRM properties. Cohort sizes of 1, 2 and 3 were also investigated by Goodman
et al. (1995) as more than one patient in a cohort will shorten the trial period and
provide sufficient information about the current dose level. However, caution should
be taken if a large cohort size is chosen, as all patients may then receive a toxic dose
level before the trial is de-escalated or stopped. Goodman et al. (1995) verify that
different cohort sizes do not lead to significant differences in the design outcome.
Although sample size is an outcome of a sequential study, the required sample
size has a monotonic relationship with the number of test dose levels. Cheung (2011)
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suggests the sample size constraint in inequality (2.9),
N − 3(K − 2)
2
>
1
φt
, (2.9)
where, N is the sample size, K is the number of test dose levels and φt is the target
toxicity probability. This constraint is not a sample size formula, but it provides some
guidelines for the appropriate sample size. For example, if the number of patients to
be enrolled is N = 32 with the target toxicity probability φt = 0.25 then the sample
size constraint suggests that K < 10. This means that the sample size is insufficient
to test 10 or more dose levels.
Some modifications made to the design methodology make the CRM more compli-
cated. This may be a reason that the CRM is not widely used in practice. For example,
incorporating multiple skeletons into the CRM will eliminate the uncertainty in the
specification of the skeleton. Yin and Yuan (2009b) used a Bayesian model averaging
technique in handling multiple skeletons. An alternative approach to Bayesian model
averaging is the Bayesian model selection. Bayesian model selection techniques
proposed by Daimon et al. (2011) fit a CRM model for each skeleton, and then select
the best model based on either posterior model probability, posterior predictive loss
or the deviance information criterion. However, these approaches require clinicians
to specify multiple skeletons and prior probabilities for each model. This means
clinicians have to guess a few toxicity probabilities for each dose level and a prior
probability for each model. Several guesses need to be made in this approach and,
therefore, these modifications of the CRM are not attractive to clinicians.
Three important modifications to the original CRM are somewhat related to the
dose-finding design methodologies developed in this thesis, and therefore, this chapter
discusses these modifications in detail. A major problem in conducting a phase I
clinical trial is the delay in enrolling patients due to the lack of previous patient
toxic outcome. The time-to-event CRM (TITE-CRM) is an extension of CRM which
enrols patients when they become available. Section 2.4 discusses TITE-CRM and
its superiority in the dose-finding design context. The original CRM is a univariate
design methodology which is based on toxicity only. It was further extended by
Braun (2002) as a bivariate dose-finding design methodology. Section 2.5 presents
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an extension of the CRM which estimates the OBD based on toxicity and efficacy
outcomes. Piantadosi et al. (1998) made a pragmatic modification to the CRM, which
eliminates the use of a skeleton and instead uses actual prior data. Their modification
is efficient, flexible and requires minimal prior data. Section 2.7 explains pragmatic
versions of the CRM.
2.4 Time-to-Event CRM
The time-to-event CRM determines a dose for the next patient based on the infor-
mation of patients who have completed their follow-up time. If toxicity is observed
then the patient’s follow-up time ends, otherwise the patient is followed for a fixed
period of time. Most dose-finding trials are set with a long follow-up time which
delays the entire drug development process. For instance, to capture long term toxicity
in phase I trials of cytotoxic drugs, patients should be monitored for at least 12 months
(Goodman, 1992). If DLT is not observed in the first patient, the second patient cannot
be enrolled for 12 months. The original CRM and other phase I clinical trial design
methods are not suitable for trials with a long follow-up period.
Late onset-toxicities are expected in most phase I trials. For example, a trial where
each patient receives an administered dose of up to six 30-day cycles of treatment
means that the usual phase I strategy accounts only for the toxic outcomes in the
first cycle (patient follow-up time is the first 30 days). Therefore, toxicity that might
occur at a later cycle is left out. If late onset toxicity is expected, then each patient
should be followed for 180 days. Therefore, each patient has to wait 180 days before
a dose decision is made. To enrol patients when they become available while using a
long patient follow-up time, Cheung and Chappell (2000) proposed the time-to-event
continual reassessment method (TITE-CRM).
The TITE-CRM is a fully sequential design that uses information from partially
followed patients. To include partially followed patients who do not have DLT, the
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TITE-CRM uses the weighted likelihood defined by,
p(y1:n,n+1|w1:n,n+1, βt, di) =
n∏
i=1
[wi,n+1ξt(di, βt)]
yi,n+1
× [1− wi,n+1ξt(di, βt)]1−yi,n+1 , (2.10)
where, yi,n+1 is the toxicity indicator for patient i just prior to the entry of patient n+1
and wi,n+1 is the weight assigned to the patient i just prior to the entry of patient n+1.
A detailed explanation of the toxicity indicator and the weight is given later in this
section. The function ξt has the same definition as in equation (2.1).
Let φt be the target toxicity probability. If patient n + 1 is available to enter the
trial the patient will be treated with dose dl ∈ (d1, . . . , dK), if and only if,
|ξt(dl,E[βt|y1:n,n+1])− φt| < |ξt(dj,E[βt|y1:n,n+1])− φt|, j = 1, . . . , K, dl 6= dj,
(2.11)
where, E[βt|y1:n,n+1] is given by,
E[βt|y1:n,n+1] =
∫
βt p(y1:n,n+1|w1:n,n+1, βt, di) p(βt) dβt. (2.12)
The weighted likelihood function in equation (2.10) is the key difference between
the CRM and the TITE-CRM. The DLT indicator yi,n+1 is an increasing function of
n. Further, if yi,n = 1 ⇒ yi,n′ = 1 ∀n′ > n. Let N be the total number of patients
selected for the trial, then yi,N+1 is a binary indicator of DLT at the end of the trial. The
weight wi,n+1 is an increasing function of patient i’s follow-up time, and wi,n+1 = 1 if
patient i completes the follow-up time or experiences DLT. The weighted likelihood in
equation (2.10) does not reflect the present toxicity status. That is, the weight wi,n+1 is
an approximation of the weight function that depends on the follow-up time of patient
i. The derivation of the weight function and the likelihood function based on the
current toxicity status is explained below.
Let CM be the maximum follow-up time for each patient, which should be speci-
fied in the phase I clinical trial protocol. Let Ui (Ui ≤ CM) be the time-to-toxicity of
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patient i. For a given time c ≤ CM ,
Pr(Ui ≤ c|di) = Pr(Ui ≤ CM |di) Pr(Ui ≤ c|Ui ≤ CM , di). (2.13)
According to the original CRM the marginal toxicity probability of patient i is given
by,
Pr(Ui ≤ CM |di) = ξt(di, βt). (2.14)
In TITE-CRM, the weight function w(c;CM , di) is used as an approximation for the
distribution Pr(Ui ≤ c|Ui ≤ CM , di). Suppose n patients enter the trial. Let Ci,n+1
be the follow-up time of patient i just prior to the entry of patient n + 1. Since the
censoring time of patients is determined by the arrival time of new patients, Ci,n+1
is independent of Ui, for all i. The likelihood function based on the current toxicity
status is given by,
p(y1:n,n+1|C1:n,n+1, di) =
n∏
i=1
[Pr(Ui ≤ Ci,n+1|di)]yi,n+1
× [1− Pr(Ui ≤ Ci,n+1|di)]1−yi,n+1 . (2.15)
From equations (2.13) and (2.14), the likelihood function in (2.15) can be written as,
p(y1:n,n+1|C1:n,n+1, βt, di) =
n∏
i=1
[w(Ci,n+1;CM , di)ξt(di, βt)]
yi,n+1
× [1− w(Ci,n+1;CM , di)ξt(di, βt)]1−yi,n+1 . (2.16)
The weight wi,n+1 in the weighted likelihood given in (2.10) is an approximation of
the weight function w(Ci,n+1;CM , di) in (2.16).
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A linear weight is the simplest choice for w,
w(c;CM , di) =

0 if c = 0
1 if c ≥ CM
min
(
c
CM
, 1
)
otherwise.
(2.17)
The TITE-CRM is motivated from long follow-up phase I trials with late-onset
toxicities. This method allows for staggered patient accrual without waiting for pre-
vious patient toxicity response. The major problem in phase I trials is resolved.
However, when the maximum follow-up time (CM in equation 2.16) is long and
patients accrue quickly (whenever they become available), the TITE-CRM results in
rapid dose-escalation. As a result, a majority of patients will be given high toxic doses
before any toxicity is observed. A modification made to the TITE-CRM by Polley
(2011) controls the number of patients given high toxic doses.
Another issue with long patient follow-up time is early patient withdrawal. If a
patient withdraws prematurely without experiencing any occurrence of adverse events,
the time to occurrence of toxicity is not known. The TITE-CRM does not specify a
censoring technique. Thall et al. (2005) investigated practical issues in monitoring
event times in early phase clinical trials. A suggestion to handle early patient with-
drawal is the incorporation of the censoring techniques discussed by Thall et al. (2005)
into the TITE-CRM. However, this is not considered in this thesis.
Although the TITE-CRM provides a simple solution for late-onset toxicities, it
creates further problems such as rapid dose-escalation and early patient withdrawal.
This is because the only difference between TITE-CRM and the original CRM is the
weighted likelihood. A statistical technique that can be used for late-onset outcome
is the renowned Expectation Maximisation (EM) algorithm (Dempster et al., 1977).
Yuan and Yin (2011) first integrated the EM algorithm to the original CRM. However,
the EM algorithm would be much more effective for bivariate dose-finding designs,
where an outcome is observed on time (before endpoint) and the other is delayed. That
is, the information from the observed outcome can be used with the EM algorithm in
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order to yield a better estimate of the parameters.
A Computer Program for the TITE-CRM
The TITE-CRM methodology is implemented in the dfcrm - R statistical software
package (Cheung, 2010). The dfcrm, short for “dose finding by continual reassess-
ment method”, mainly focuses on CRM and TITE-CRM. The first version dfcrm
v0.1-1 was released on August 20, 2008 and is continuously being developed with the
latest version v0.2-2, released on August 29, 2013. The R software program should
be installed first to use the dfcrm. However, the user does not have to be proficient in
the use of the R software package.
A 19 page reference manual can be found at the CRAN web site. The manual
can be easily accessed online by typing “?crm” in the ‘R Console’ window when
connected to the internet. The ‘pdf’ version of the manual contains nine sections,
in each section a dfcrm command is explained. For instance, ‘Executing the TITE-
CRM’ is a section with a short description of the command ‘titecrm’, usage of the
command, explanation of command arguments and a reference. The journal article
that first published the design method is the reference added to each section, making
it easy for user who wants to understand the design methodology. An example written
at the end of each section illustrates the functionality of each command.
dfcrm Version 0.2-2 Features
The R package ‘dfcrm’ consists of simple functions to implement the CRM. For
instance, using either the power model (2.3) or logistic model (2.4), the ‘dfcrm’ takes
cohorts of patients’ DLT outcomes and recommends a dose level for the next cohort of
patients based on the condition (2.8). This package also contains functions to design
the original CRM. The simulation features of this package allow the user to analyse
operating characteristics of a design (‘crmsim’ and ‘tiesim’ commands). Additional
features of the dfcrm include model sensitivity checking and calibration of the skeleton
using ‘indifference intervals’.
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dfcrm Version 0.2-2 Limitations
Although dfcrm has many features for phase I clinical trial design using CRM, there
are some features missing. These include a method for bivariate CRM (Section 2.5).
Furthermore, no stopping rule is implemented in the software package. To ensure
patient safety, a stopping rule based on a posterior toxicity probability should be im-
plemented. The ‘crm’ command implements a single trial by allowing dose-escalation
by more than one dose level. This means the user has to ensure patient safety manu-
ally. Furthermore, simulation features do not allow the running of multiple scenarios
simultaneously.
A graphical summary of the trial is built-in, but most necessary plots such as
dose levels versus initial skeleton, dose levels versus posterior probability of toxicities
and patient accrual duration for TITE-CRM are missing. A proficient R user could
add user-written functions by editing the R script in the file ‘dfcrm.R’. Appendix A
provides a simulation study based on this software program.
2.5 Bivariate CRM
The bivariate dose-finding design concept, sometimes known as phase I-II design,
was developed just over a decade ago. The primary objective of this design is to
estimate an OBD by jointly evaluate toxicity and efficacy. Zohar and Chevret (2007)
and Thall (2012) review bivariate dose-finding design methodologies. The CRM is ef-
ficient in estimating the optimal dose in univariate dose-finding designs, and therefore,
O’Quigley et al. (2001) first proposed a simple bivariate version of the CRM. Their
approach is not appealing because it does not estimate the interaction between toxicity
and efficacy. The bivariate design developed by Braun (2002) separately parametrises
both toxicity and efficacy outcomes for each dose level and then combines them into a
joint likelihood model. This likelihood model has an additional parameter to measure
the toxicity-efficacy interaction.
The bivariate CRM (bCRM) proposed by Braun (2002) accounts for the marginal
dose-toxicity and dose-efficacy relationships separately. It uses a bivariate distribution
to measure the interaction effect between toxicity and efficacy.
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Let Pt1 , . . . , PtK and Pe1 , . . . , PeK be the skeletons for toxicity and efficacy of K
dose levels of the trial. The bCRM assumes a one-parameter dose-response model for
toxicity and efficacy separately,
Pr(T = 1|di, βt) = ξt(di, βt), i = 1, . . . , K (2.18)
Pr(E = 1|di, βe) = ξe(di, βe), i = 1, . . . , K; (2.19)
where, {T = 1} and {E = 1} represent dose limiting toxicity and desired efficacy
respectively. To ensure monotonicity in the dose-response relationship, parameters
are set to be positive. The dose di = 0.5(ξ−1t (Pti) + ξ
−1
e (Pei)). The most common
choices of the monotonic function ξt and ξe are given by,
ξt(di, βt) =
exp(−α0 + βtdi)
1 + exp(−α0 + βtdi) , ξe(di, βe) =
exp(α0 − βedi)
1 + exp(α0 − βedi) ; (2.20)
where α0 is a constant that is not estimated.
Let (yi, zi) be the bivariate indicator of toxicity and efficacy, respectively. Let ψ ∈
(0,1) be a constant across all dose levels such that ψ/(1−ψ) is the cross-ratio between
y and z. The non-standard bivariate likelihood, used by Braun (2002), is given by,
p((yi, zi)i=1:n|βt, βe, ψ, di) ∝
n∏
i=1
ξt(di, βt)
yi(1− ξt(di, βt))(1−yi)
× ξe(di, βe)zi(1− ξe(di, βe))(1−zi)
× ψyizi(1− ψ)(1−yizi). (2.21)
Let the prior information of (βt, βe, ψ) be given by a joint prior distribution p(βt, βe, ψ).
Braun (2002) recommends,
p(βt, βe, ψ) = 6ψ(1− ψ) exp(−βt − βe). (2.22)
That is, βt, βe ∼ Expon(1) and ψ ∼ Beta(2, 2). The posterior distribution is given
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by,
p(βt, βe, ψ|(yi, zi)i=1:n) ∝ p(βt, βe, ψ) p((yi, zi)i=1:n|βt, βe, ψ, di). (2.23)
The expected posterior toxicity probability and the expected posterior efficacy proba-
bility for each dose are given by,
ξt(di) =
∫
ξt(di, βt) p(βt, βe, ψ|(yi, zi)i=1:n) dβt,
ξe(di) =
∫
ξe(di, βe) p(βt, βe, ψ|(yi, zi)i=1:n) dβe.
Let φt be the target toxicity probability and φe be the target efficacy probability.
The dose dl ∈ (d1, . . . , dK) will be selected if and only if,
(ξt(dl)− φt)2 + (ξe(dl)− φe)2 < (ξt(dj)− φt)2
+ (ξe(dj)− φe)2; j = 1, . . . , K, l 6= j.
The bCRM uses both toxicity and efficacy as bases for dose escalation or de-
escalation. The bCRM parameters cannot be estimated until at least one patient with
one of the following outcomes is observed: no toxicity and no efficacy, toxicity and
no efficacy, efficacy and no toxicity, and both toxicity and efficacy. Therefore, this
design methodology is impractical. In reality the efficacy endpoint takes too long
to observe making this design concept unrealistic. Another issue with bCRM is the
monotonic assumption of the dose-efficacy relationship. Efficacy can be monotone
increasing, decreasing or uni-modal. Although use of cross-ratio as an interaction
parameter is a beneficial feature of this design, the bivariate distribution is unknown in
the statistics literature. Furthermore, the bivariate distribution assumes the interaction
effect is constant across all doses, therefore, the interaction effect cannot be estimated
at each dose level.
A Computer Program for the bCRM
The bCRM Version 1.1.3 is a menu driven freeware available at the M.D. Anderson
Cancer Center’s software download site (Lloyd et al., 2005). This software program
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is specially developed to design phase I clinical trials based on the bivariate CRM. A
few ad hoc rules to the CRM introduced by Goodman et al. (1995), are incorporated
in this software program.
A 13 page installation guide can be downloaded from the software web site. Three
additional documents for running simulations, single trials, and describing test re-
sults can be downloaded from the software home page. The user-guide for running
simulations is a 49 page documentation which includes numerous screen-shots. This
document also provides simulation outputs. The user-guide for running a single trial
is a 17 page document that guides the user in designing and managing a single trial
based on simulations conducted. The last document which is 20 pages verifies that the
examples shown in Goodman et al. (1995) and Braun (2002) yield the same results in
this software program. All three documents are well-written and provide step-by-step
guides for users.
bCRM Version 1.1.3 Features
The bCRM Version 1.1.3 is an easy-to-use package with a well-designed graphical
user interface. The software program includes the one-parameter logistic models
explained in equation (2.4), and the user can select a value for the constant α0. Fur-
thermore, as the user can turn off the efficacy part of the bivariate CRM, the CRM in
Section 2.2 with the one parameter logistic model can be used to estimate the MTD.
A number of graphs are built-in with the bCRM Version 1.1.3 software program.
The design window contains a graphical display of the skeleton for different values
of slopes (βt and βe). This software program provides a number of outputs. Figure
2.2 shows how the user can control the output variables. A histogram is produced in
the graph manager for each variable selected. Graphical displays of scenario toxicity
results and distribution of OBD are also built-in with the bCRM version 1.1.3.
bCRM Version 1.1.3 Limitations
This software program is primarily based on the method proposed by Braun (2002),
and therefore it has all the limitations of the methodology discussed above. The soft-
ware program does not incorporate the power model in equation (2.3). The user cannot
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Figure 2.2: A screen-shot in bCRM software program
select prior distributions for βt, βe and ψ. Although there is an option in designing
the CRM with toxicity outcome only, the software program lacks completeness of the
dose-finding trial using CRM. That is, other important CRM modifications, such as
TITE-CRM, cannot be conducted using this software program. A simulation study in
Appendix A illustrates the functionality of this software program.
2.6 The CRM for Combined Drugs
Simultaneous use of drugs is widely known choice in deadly disease settings in
order to produce joint treatment effect. The joint drug effect can be antagonistic,
synergistic, or additive. This joint drug outcome is expected to reduce toxicity, in-
crease therapeutic effect and minimise dosage failure or drug tolerance (Chou, 2010).
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Concurrent development of two or more investigational new drugs (INDs) provides
less information about safety of the individual drugs than if the individual drugs
were developed alone. Therefore, co-development of INDs begins after evaluating
the safety profile of the individual drugs separately in humans. Several dose-finding
design methodologies are proposed for the first critical step of phase I drug combina-
tions trials. This section criticises the dose-finding design methodologies proposed in
the literature for phase I drug combination trials.
An unattractive approach is to consider fixing one dosing regimen of a drug and
escalate the doses of other drug and repeat the process by fixing every single test
dose level. This approach is impractical and not guaranteed to yield an accurate
MTD combination. A different approach is to start at the lowest dose level of each
drug and escalate or de-escalate until a clinical endpoint is reached. The choice
of dose escalation and de-escalation procedures should be scientifically valid and
rational to clinical practice. Although several escalation procedures are proposed in
the statistical literature, most of those ignore the joint drug action and the concept
of interaction. For instance, Kramar et al. (1999) first attempted to extend the CRM
for drug combinations trials. They developed ad-hoc rules for the CRM which order
dose-combinations. Braun and Wang (2010) proposed a Bayesian hierarchical design
which ignores the interaction effect for simplicity. Recently proposed partial ordering
techniques ignore the drug-drug interaction (Wages and Conaway, 2013, Wages et al.,
2011, 2013a,b). The ultimate purpose of drug combination trial is to study the joint
drug effect, and therefore, these one-dimensional optimisations do not assure joint
optimum MTD combinations.
Multi-dimensional search on dose-combinations with estimated joint toxicity prob-
ability is necessary to identify reliable optimum dose combinations. Berry et al.
(2011) and Yin (2012) describe all the drug combination design methodologies which
explore the design space (the combination of doses) more fully than typical ordered
one-dimensional dose-finding allows. These design methodologies estimate the joint
toxicity probability and use a two-dimensional search for drug combination trials. No-
tably, Thall et al. (2003) use a six parameter model for the joint toxicity probabilities.
This model is over parametrized, two parameters for marginal toxicity of each drug
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and an additional parameter for a joint effect is sufficient. Yin and Yuan (2009a,c)
use copula type regressions to estimate the joint toxicity probabilities. Their dose
escalation strategies over the dose combination space are reminiscent of the CRM.
However, their use of copula is not always suitable to estimate the joint toxicity
probability (Gasparini, 2013). In addition, their assumptions of the interaction effect is
independent of dose levels is insufficient to capture the complex joint effect. Currently,
there is no standard design methodology for phase I drug combination trials.
2.7 A Pragmatic CRM
Although the CRM is an elegant dose-finding design methodology, the require-
ment of a skeleton and a prior distribution for the model parameter are exacting.
Different skeletons and prior distributions will lead to different design properties.
There is insufficient information to justify which skeleton and prior distribution are
appropriate in practice. Furthermore, as a trial progress the amount of information the
skeleton and the prior distribution carry are neither down weighted nor diminished.
For these reasons, O’Quigley and Shen (1996) first proposed a pragmatic version
of the CRM based on the maximum likelihood estimation (MLE) method. They
prove that the important features of the CRM remain unchanged with the use of
MLE. However, to apply the MLE an observation from each outcome (DLT and non-
DLT) is a required. They use conventional design methodology to obtain these initial
observations then switch to the CRM. Therefore, their design methodology is two-
stage which implies it is not a coherent design (Cheung, 2005). Piantadosi et al. (1998)
proposed a better pragmatic CRM using the MLE. They incorporate prior data of a
low and high toxic dose level, use this data to estimate the initial values of the model
parameters, and down weight the information this prior data carries using weights.
The use of MLE is rather appropriate because dose-finding design methodologies
are way of collecting data in which incoming data is unknown and random, and the
fixed parameter values are first estimated using the prior data, then updated after every
sequence of the data collection.
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2.7.1 Modelling Issue with the CRM
The original CRM and its modifications discussed above use a single parameter model
under the Bayesian paradigm. A visual display of the assumed model is crucial
for thoroughly understanding the dose-response relationship. One important ques-
tion is whether a single parameter model thoroughly describes the dose-response
relationship. Dose-finding trials are conducted in small samples and their operating
characteristics are heavily dependent on the mathematical formulation of the model.
Although Shen and O’Quigley (1996) prove that the CRM is capable of estimating
a reliable optimum dose under a misspecified model, one parameter is insufficient to
capture the true dose-response relationship with small samples. O’Quigley (2002b)
supports this argument, single parameter models perform poorly in reproducing the
true dose-response curve. Therefore, the pragmatic version of the CRM uses multi-
parameter logistic models.
Logistic models are widely used to describe univariate variables with binary re-
sponses. This thesis assumes that the mathematical structure of the logistic model
perfectly represents the monotonically increasing dose-toxicity relationship. This
model can be extended to represent the dose-efficacy relationship. Dose-finding trials
are a scientific data collection process, in which the statistical model with adequate
parameters is a recipe for producing data. The data is used to estimate the model but
the model is specified first before we see the data. Therefore, sequentially incoming
data is fitted to the assumed model. The converse of this, model fit to the data, is
incorrect in the data collection process. This misconception led to the development
of erroneous dose-finding design methodologies based on model selection processes
(Daimon and Zohar, 2013). There is no right or wrong model, but the models based
on the well-known sigmoid curve perfectly imitate the dose-response relationship.
For these reasons, this thesis ignores model checking, model selection, and model
averaging statistical techniques in the dose-finding design methodologies.
Considering the dose-toxicity relationship, the toxicity probability of lower dose
levels are closer to zero, which increase with increasing dose levels and remain close
to one for higher toxic dose levels. As given in equation (2.24) below at least two
parameters for binary responses ensures the intercept αt and slope βt are determined
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by the actual data.
ξt(d, αt, βt) = log
{
Pr(T = 1)
1− Pr(T = 1)
}
= αt + βtd. (2.24)
The model in equation (2.24) resembles important features of the dose-toxicity rela-
tionship. Toxicity is defined by probability, and therefore, it stays between zero and
one as the dose d increases. The relationship between toxicity probability and d is
non-linear. That is, when dose d gets smaller the toxicity probability approaches zero
at a slower rate than dose. The probability slowly approaches to one when the dose
becomes very large. This model represents subtle difference in real data and it does
not contain unnecessary complications. The intercept parameter αt is the value of
the log-odds of toxicity presence when the administered dose is zero. This parameter
should not be fixed as a constant, as in equation (2.4), in order to capture the true
dose-toxicity relationship accurately.
A simple extension of the model in equation (2.24) is a well known model for
ordinal outcomes. If toxicity is observed on a 1 to 4 ordered scale then the cumulative
logistic model given in equation (2.25) is capable of handling ordinal outcomes.
ξt(d, γtjt , δt) = log
{
Pr(T ≥ jt)
Pr(T < jt)
}
= γtjt + δtd, jt = 2, 3, 4 (2.25)
where jt is the cut-point at which toxicity T is dichotomised. The ordinal variable T
has four ordered levels. This implies that three logits are formed. The three specific
logit comparisons are: T ≥ 2 versus T < 2, T ≥ 3 versus T < 3, and T ≥ 4 versus
T < 4. For jt = 1, the denominator of the odds, Pr(T < 1) = 0 and therefore the
odds is not defined. For each cut-point jt, there is an intercept parameter γtjt . The
slope parameter δt does not depend on jt. This means the effect of dose d is identical
at each cut-point jt.
The logistic models explained in equations (2.24) and (2.25) are quantitatively
correct and flexible in resembling the monotonic dose-toxicity relationship. For these
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reasons, the novel dose-finding designs developed in this thesis use multi-parameter
logistic models.
2.7.2 Incorporating Prior Knowledge to the CRM
The CRM uses a prior distribution for the single model parameter. This prior distribu-
tion carries no clinical information. Generally, a Normal distribution with mean zero
and small variance (any value less than two) is used as the prior distribution for the
model parameter. This prior distribution is merely a computational device in the CRM.
However, the CRM has a dilemma for incorporating clinicians’ expert knowledge into
the design methodology. Clinicians have to specify the toxicity probability of each
dose level. This is complicated for clinicians as it can be difficult to identify the
toxicity probability of each dose level. Although methods have been proposed to
calibrate prior distribution parameters along with toxicity probability of each dose
level, it does not simplify the difficulty in incorporating clinical information into the
model (Lee and Cheung, 2011).
Piantadosi et al. (1998) introduced a pragmatic version of the CRM with binary
toxicity outcomes, which uses toxicity probability of a low and a high dose level as
the prior knowledge to estimate the design parameters. This prior data can be obtained
from pre-clinical studies or from drugs which have pharmacological effects similar to
the investigational new drug (IND). These dose levels need not be the test dose levels.
This prior data is also used to estimate the starting dose and to proceed the trial with
a small amount of adverse event responses. Contribution of prior data throughout the
design is crucial and reasonable, because dose-finding trials are conducted in small
sample sizes. If there is a reason to have prior data of low and high doses then the
amount of information prior data carries as the trial progresses should be reasonably
diminished. Caution should be taken as a trial will fail if there are no heterogeneity
outcomes in the current data with prior data being weighted out. For instance, if prior
data is eliminated before a patient is observed with a toxicity outcome then parameters
of the model in equation (2.24) cannot be estimated.
Table 2.1 shows an example of two different weighting schemes for prior data.
These weights are created with a cohort of size four. The first weighting scheme,
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Table 2.1: A prior data weight distribution
Cohort 2:1-Scheme 1:1-Scheme
No. Prior data Observed data Prior data Observed data
1 66.67 33.33 50.00 50.00
2 50.00 50.00 33.33 66.67
3 40.00 60.00 25.00 75.00
4 33.33 66.67 20.00 80.00
5 28.57 71.43 16.67 83.33
6 25.00 75.00 14.29 85.71
7 22.22 77.78 12.50 87.50
8 20.00 80.00 11.11 88.89
9 18.18 81.82 10.00 90.00
10 16.67 83.33 9.09 90.91
11 15.38 84.62 8.33 91.67
namely the ‘2:1-Scheme’, uses two times the cohort size as the prior data weight.
For instance, once the first cohort of four patients are entered into the trial the prior
data has double the amount, eight. So the total weight prior data carry is equal to
8
12
×100%. This weighting scheme starts with over 65% weight on prior data and is
gradually reduced to 25% when the sixth cohort of patients is entered into the trial.
The second weighting scheme is named the ‘1:1-Scheme’, which ensures the prior
data weight is equal to the cohort size. It starts with 50% and ends with just over 8%
weight for prior data.
2.7.3 Safety Constraint and Stopping Rules
Dose-finding trials are set to an early halt for safety or futility reasons. Zohar (2006)
discusses several stopping rules for dose-finding designs based on sound statistical
procedures. Safety constraints or stopping rules affect the operating characteristics of
the dose-finding design methodologies. O’Quigley (2002a) investigates the operating
characteristics of the CRM with early termination. Although stopping rules are en-
tirely the clinicians’ choice, these rules can be based on updated toxicity or efficacy
probabilities or observed data. Stopping rules based on observed data are empirical
and simple to implement. Safety constraints and stopping rules discussed below are
intuitive.
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A safety constraint based on estimated toxicity probability of a dose level will
increase patients’ safety by selecting the adjacent lower dose level of an estimated
dose level only if the estimated toxicity at the dose level is over ct% higher than
the toxicity cut-off. This prevents a dose level being selected for the next cohort of
patient that has the estimated toxicity probability larger than the toxicity cut-off plus
the margin ct%. If the estimated dose level is the lowest dose level with the toxicity
probability over ct% higher than the toxicity cut-off, then the trial will stop early. This
safety constraint behaves as a stopping rule whenever the lowest dose level is highly
toxic. The highest level of safety can be implemented by setting this constraint level
to be equal to zero.
A safety stopping rule stops the trial if adverse events recorded are over st%
of all enrolled patients. If patients are allocated to higher toxic dose levels then
more adverse events will be recorded, and therefore, the trial will stop whenever the
recorded adverse event percentage is greater than st%. If st is set to be less than 100%
and all patients enrolled to the starting dose experienced toxicity then this rule will
stop the trial early and declare the starting dose is highly toxic. If the IND is expected
to produce mild toxicities then a wise choice for st would be a decreasing stepwise
function. That is, a higher value is give for st when the first cohort of patients is
enrolled then the value decreases stepwise for each subsequent cohorts.
In bivariate dose-finding trials, if the IND does not produce enough desired effi-
cacy (DE) outcomes then it is not worth continuing the trial. A futility stopping rule
stops the trial if observed DE are less than sf% of all enrolled patients. Premature
stopping can be prevented by setting sf to be zero for the first few cohorts of patients.
In actual dose-finding designs clinicians decide on safety constraints and stopping
rules.
2.7.4 Practical Implementation of Binary CRM
If toxicity is observed as the binary outcome presence or absence of DLT then our
binary (Bin) version of the CRM described below is feasible to implement in practice
(Darssan et al., 2013). Toxicity T is observed as a binary (0,1) outcome, where 0 is a
‘non DLT’ and 1 is a ‘DLT’. The design methodology for binary CRM is as follows.
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1. Determine the initial CRM design parameters: target toxicity probability φt,
number of test dose level K and sample size N , and verify the sample size
constraint in equation (2.9).
2. Obtain prior toxicity data of a low and a high dose level. For instance, 200 mg
produces 5% DLTs and 3000 mg produces 85% DLTs. Decide on the amount
of information prior data carries as the trial progresses (Section 2.7.2).
3. Specify the dose-toxicity model in equation (2.24) and estimate the model pa-
rameters αt and βt using maximum likelihood estimation, giving αˆt and βˆt,
respectively.
4. Implement the safety constraint and the stopping rule in Section 2.7.3. Use the
inequality in (2.26) to find the dose level (dl) which has toxicity probability
closest to the target toxicity probability.
|ξt(dl, αˆt, βˆt)− φt| < |ξt(di, αˆt, βˆt)− φt|, i = 1, . . . , K, di 6= dl. (2.26)
5. Update the values of αˆt and βˆt once toxicity outcomes of the newly entered
cohort of patients are known.
6. The dose level selected for the final cohort of patients is the MTD. The MTD is
a dose with estimated Pr(T = 1) closest to the target toxicity probability.
The Bin-CRM described by Darssan et al. (2013) is slightly different from the
pragmatic CRM design introduced by Piantadosi et al. (1998). Piantadosi et al. (1998)
use a continuum of test doses. The continuous dose range is neither physically possi-
ble nor feasible in general clinical settings. We modified the method for discrete dose
levels using the sample size constraint in inequality (2.9) and the CRM dose selection
criterion in inequality (2.8). This sample size constraint provides a guideline for the
number of test dose levels to be used. The CRM dose selection criterion selects the
dose level which is closest to the target toxicity probability.
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2.7.5 Practical Implementation of Ordinal CRM
Incorporating severity of adverse events into the dose-toxicity model will bring forth
more information about low and high grade toxicities. If toxicity is recorded as an
ordinal outcome a two-parameter logistic model is insufficient to incorporate more
toxicity information. Several attempts have been made to incorporate ordinal tox-
icity outcomes into design methodology. Notably, Bekele and Thall (2004) use a
multivariate ordinal probit regression model, and Yuan et al. (2007) use a quasi-
Bernoulli likelihood. These designs are complicated, computationally challenging and
barely comply with dose-finding designs in practice. Recently, Iasonos et al. (2011)
present a multi-stage CRM type design which incorporates low grade toxicity into the
CRM design methodology. Their approach amalgamates higher grade toxicities and
therefore disaggregated information on those toxicities is lost. Meter et al. (2011) use
the cumulative logistic model in equation (2.25) to describe the relationship between
dose and ordinal toxicity. This cumulative logistic model with different intercept
parameters corresponding to each toxicity grade is capable of providing additional
information on low and high grade toxicities. In addition, a simple binary DLT cut-off
(e.g., toxicity grade of 3 or more is a DLT) can be used to estimate dose levels.
If toxicity T is observed on a 1 to 4 ordered scale, with adverse event scores of 1 to
4 being ‘mild’, ‘moderate’, ‘severe’ and ‘life-threatening’ adverse events, respectively
then our ordinal (Ord) version of the CRM incorporates the adverse event severity
information into the design methodology (Darssan et al., 2013).
1. Determine the initial CRM design parameters: target toxicity probability φt,
number of test dose level K and sample size N , and verify the sample size
constraint in equation (2.9).
2. Decide on adverse event scores which are ‘dose-limiting’. For instance, adverse
event scores of 3 and 4 are ‘dose-limiting’.
3. Obtain prior toxicity data of a low and a high dose level. For instance, 200 mg
is 10% toxic with 75% of these toxic events being mild, 20% moderate, 4%
severe and 1% life-threatening adverse events. Similarly, 3000 mg is 90% toxic
with 5% of these toxic events being mild, 10% moderate, 35% severe and 50%
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life-threatening adverse events. Decide on the amount of information prior data
carries as the trial progresses (Section 2.7.2).
4. The cumulative logistic model in (2.25) describes the dose-toxicity relationship.
Estimate the model parameters γtjt and δt using maximum likelihood estima-
tion, giving γˆtjt and δˆt, respectively.
5. Implement the safety constraint and the stopping rule in Section 2.7.3. Use the
inequality in (2.27) to find the dose level (dl) which has toxicity probability
closest to the target toxicity probability.
|ξt(dl, γˆt3, δˆt)− φt| < |ξt(di, γˆt3, δˆt)− φt|, i = 1, . . . , K, di 6= dl. (2.27)
6. Update the values of γˆtjt (jt = 2, 3, 4) and δˆt once toxicity outcomes of the
newly entered cohort of patients are known.
7. The dose level selected for the final cohort of patients is the MTD. The MTD is
a dose with estimated Pr(T ≥ 3) closest to the target toxicity probability.
Meter et al. (2011) introduced the ordinal CRM for continuous dose range. We
slightly modified it for discrete test dose levels as explained in Section 2.7.4.
2.8 Issues with the Pragmatic CRM
The uncertainty of the observed toxicities (if it was related or not to the IND) is not
incorporated into the CRM design methodology. All proposed design methodologies,
including the CRM only take into account the adverse events which are definitely
related to the IND. Adverse events which have possible or doubtful relationships to
the IND are either ignored or wrongly included in the design as definitely related to
the IND, which implies the estimated MTD is potentially inaccurate. If an adverse
event is observed during a clinical trial then the relationship of that adverse event to
the IND must be thoroughly identified (Hughes, 1995). A conventional classification
of adverse event relatedness is ‘doubtful’, ‘possible’, ‘probable’, and ‘definite’ (Karch
and Lasagna, 1975). Incorporating this classification into the pragmatic CRM would
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yield a better MTD estimation. Chapter 3 develops a novel design methodology which
incorporates adverse event relatedness into the pragmatic CRM.
The pragmatic CRM is not extended to estimate an OBD. An extension is neces-
sary to monitor the monotone increasing, decreasing or uni-modal forms of the dose-
efficacy relationships. In addition, the CRM is incapable of predicting the late onset
efficacy outcome. A prediction of late onset efficacy outcome using the available
toxicity outcome and its interaction with the efficacy outcome is necessary to esti-
mate a reliable OBD. Furthermore, additional information on desired efficacy (e.g.,
‘progressive’, ‘stable’ and ‘remissive’) is not incorporated in to the pragmatic CRM.
Chapter 4 extends the pragmatic CRM for bivariate dose-finding clinical trials.
Another issue is that the pragmatic version of the CRM is not modified to de-
sign drug combination trials. Several model based designs have been proposed for
drug combination trials. A few attempts were made to extend the CRM to evaluate
joint drug effect. However, there are no dose-finding design methodologies which
accurately capture the joint drug effect. Chapter 5 introduces a novel phase I drug
combination design methodology which is an extension of the pragmatic CRM.
To conclude, the CRM is a renowned dose-finding design methodology which has
generated extensive literature, much of which proves CRM to be robust in estimating
MTD. The original CRM and its crucial modifications are ignored in practice. The
pragmatic versions of the CRM are simple, scientifically valid, and adequately incor-
porate prior information on the dose-toxicity relationship. However, the pragmatic
CRM is not extended to conduct bivariate dose-finding trials and phase I drug combi-
nation trials. The CRM and all other dose-finding designs do not incorporate adverse
event relatedness into the design methodology. This leads to inaccurate optimum
dose estimation. Chapter 3 develops a novel dose-finding design methodology which
uses both Bin-CRM in Section 2.7.4 and Ord-CRM in Section 2.7.5 and incorporates
adverse event relatedness.
Chapter 3
Adverse Event Relatedness Continual
Reassessment Method
Synopsis
This chapter incorporates adverse event relatedness into the CRM as published
in Darssan et al. (2013). Adverse events observed during a phase I trial may not be
related to the investigational new drug (IND). Some adverse events may be possibly
or probably related to the IND. Extending the CRM to accommodate adverse event
relatedness would lead to better MTD estimation. Simulation studies discussed in this
chapter show it is beneficial to incorporate adverse events relatedness into the CRM.
3.1 Introduction to the Design Methodology
A phase I trial conducted in developing a new drug for rheumatoid arthritis at
Roche pharmaceutical company reports adverse event relatedness on a 0 to 3 ordered
scale with a relatedness score of 0 being unrelated, 1 is remotely, 2 is possibly and
3 is probably related to the IND. The pharmaceutical company is not involved in
the work presented in this thesis. However, this phase I trial motivates the need for
incorporating an adverse event relatedness score into design methodology. The new
design presented in this chapter, namely adverse event relatedness CRM (Aerd-CRM)
combines Bin-CRM (Section 2.7.4) and Ord-CRM (Section 2.7.5) design concepts.
Suppose an adverse event is recorded on a 1 to 4 ordered scale with an adverse
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event score of 1 being mild, 2 is moderate, 3 is severe and 4 is life-threatening adverse
events. Relatedness of an adverse event to the IND is conventionally classified into
‘doubtful’, ‘possible’, ‘probable’ and ‘definite’ (Karch and Lasagna, 1975). The Aerd-
CRM incorporates this classification with a score of 1 being adverse events doubtfully
or possibly related to the IND and 2 is an adverse event probably or definitely related
to the IND.
Adverse events which have possible or doubtful relationships to the IND may
occur due to an underlying disease, environmental or toxic factors, or other drug or
therapy, or placebo effects. These background adverse reactions are produced at some
level when the dose of the IND is zero. Statistical models used in this chapter for
describing dose-toxicity relationships based on possibly or doubtfully related adverse
events account for such background adverse reactions. Possibly or doubtfully related
adverse events have a vague relationship to the IND. Since additional severity informa-
tion about these adverse events is superfluous, they are modelled as binary outcomes:
presence or absence of dose-limiting toxicity (DLT).
The Aerd-CRM is developed with the presence of ordinal toxicity outcomes. The
simple binary version of the design, namely binary adverse event relatedness continual
reassessment method (Bin-Aerd-CRM), is illustrated first. A binary toxicity response
means severe and life-threatening adverse events are classified as presence of DLT
and all other adverse events are classified as absence of DLT. Section 3.2 presents the
development and characteristics of the Bin-Aerd-CRM methodology.
An Aerd-CRM requires the following ‘design parameters’: target toxicity prob-
ability φt, number of test dose levels K, sample size N , dose toxicity model and
prior data. This chapter sets the target toxicity probability φt to be 0.25. Dose levels
tested for a rheumatoid arthritis trial at the Roche pharmaceutical company are used
for Aerd-CRM design development. The eight dose levels used in the trial are: 50
mg, 150 mg, 500 mg, 1200 mg, 1500 mg, 2000 mg, 2400 mg, and 2600 mg. Forty-
four patients are sequentially entered into the trial in cohorts of size four. The dose
toxicity model and prior data varies for Bin-Aerd-CRM and Aerd-CRM. These design
parameters are specified below under the relevant sections.
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3.2 Binary Adverse Event Relatedness CRM
3.2.1 Prior Data
Prior data for Bin-Aerd-CRM are shown in Figure 3.1. Prior toxicity data of a low
(200 mg) and a high (3000 mg) dose are specified separately in two dimensional
grids. Adverse event and relatedness responses are denoted by T and R respectively.
Adverse event responses are binary, 0 or 1, where 0 is ‘non-DLT’ and 1 is DLT.
Relatedness scores are recorded as 1 or 2, where 1 is doubtfully or possibly and 2
is probably or definitely related to the IND.
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Figure 3.1: Prior data for Bin-Aerd-CRM
The expected toxicity percent is shown at the right side of each diagram of Figure
3.1. Assume that the prior data for adverse events relating to a 200 mg dose yields 5%
DLT. Similarly, 3000 mg yields 85% DLT. This information can be determined from
DLT observed for drugs similar to the IND.
Expected relatedness percent is shown at the bottom of each diagram of Figure 3.1.
Relatedness is independent of dose, but is dependent on the IND. Assume that adverse
events recorded are 35% doubtfully or possibly and 65% probably or definitely related
to the IND. This prior data can be simply determined from adverse event relatedness
recorded for drugs similar to the IND or clinicians’ judgment.
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3.2.2 Dose Toxicity Model
The dose toxicity relationship of Bin-Aerd-CRM is specified using two logistic mod-
els. Model (3.1) below accounts for adverse events doubtfully or possibly, and model (3.2)
below for probably or definitely related to the IND. The first model contains a ‘clin-
ical parameter’, p, the proportion of toxicities which background adverse reactions
accounts for, for doubtful or possible adverse events. This clinical parameter is not
estimated, rather prescribed in advance. A value for p can be determined based
on any common underlying disease most enrolling subjects carry, environmental or
toxic factors, and other drugs or therapies given to the study subjects. A reasonable
value for p is greater than zero and less than 0.1. For the purpose of simulation this
chapter assumes doubtfully or possibly related adverse events carry 5% of toxicity
from background adverse reactions.
Pr(T = 1|R = 1, di) = p+
(
exp(αt1 + βt1di)
1 + exp(αt1 + βt1di)
)
× (1− p) (3.1)
Pr(T = 1|R = 2, di) = exp(αt2 + βt2di)
1 + exp(αt2 + βt2di)
, (3.2)
3.2.3 Dose Selection Criterion
The MTD is a dose level with estimated toxicity probability closest to the target
toxicity probability. The criterion stated in inequality (3.3) below selects a dose level
for each cohort of patients. Dose dl is selected if and only if,
|max{Pr(T = 1|R = 1, dl),Pr(T = 1|R = 2, dl)} − φt|
< |max{Pr(T = 1|R = 1, di),Pr(T = 1|R = 2, di)} − φt|,
i = 1, . . . , K, di 6= dl. (3.3)
This criterion uses the maximum of estimated doubtfully or possibly related and
probably or definitely related toxicity probability, to select a dose level. That is, for
each dose level the maximum of the estimated toxicity probability based on possibly
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related adverse events and probably related adverse events is calculated. The dose
level with the maximum toxicity probability closest to the target toxicity probability
is selected for the following cohort of patients.
3.2.4 A Simulation Study for Bin-Aerd-CRM
The simulation study in this section analyses characteristics of the Bin-Aerd-CRM. A
dose level for the first cohort of patients is estimated based on the prior data specified
in Section 3.2.1. Cell probabilities of the diagrams shown in Figure 3.1 are calculated.
This calculation assumes adverse event scores and relatedness scores are independent.
These cell probabilities are the prior toxicity probabilities of a low dose (200 mg) and
a high dose (3000 mg) for Bin-Aerd-CRM.
The prior data and models (3.1) and (3.2) are fitted, with the probabilities taken
as data. Estimated toxicity probabilities are calculated at each dose level. A dose of
1200 mg is selected as the starting dose using the dose selection criterion shown in
inequality (3.3). This dose level is the starting dose for every simulated trial in this
section. As a trial progresses the contribution of the prior data is reduced using the
weighting scheme discussed in Section 2.7.2.
Six scenarios are created for the purpose of simulation. These scenarios represent
the true toxicity probabilities of each dose level. Ten thousand trials are simulated
under each scenario. Each trial was conducted with the safety constraint and the safety
stopping rule explained in Section 2.7.3. Values given for ct and st are 10% and
75% respectively. This means that if the estimated toxicity of a selected dose level is
10% higher than the target toxicity probability then the adjacent lower dose level is
selected for the following cohort of patients. The trial will stop whenever the amount
of recorded adverse events is greater than 75%.
Table 3.1 summarises the operating characteristics of the Bin-Aerd-CRM. Under
each scenario, the first two rows of the table represent the true probabilities of toxici-
ties; the third row corresponds to the selection percentage of each dose level using the
Bin-Aerd-CRM; the fourth row is the number of patients treated at each dose level of
completed trials averaged over 10000 simulated trials. Furthermore, this table shows,
percentage of inconclusive trials (denoted as ‘Stop’), number of doubtful or possible
44 CHAPTER 3. AERD-CRM
(denoted as ‘No.{R=1}’) and number of probable or definite (denoted as ‘No.{R=2}’)
adverse events averaged over 10000 simulations.
In scenario 1, toxicity probabilities for doubtful or possible adverse events are low
in the first three dose levels. It jumps to around 30% at 1200 mg where it dramatically
increases to just over 85% at 2600 mg. The toxicity probability of probable or definite
adverse events are 15% at 500 mg with a jump to just under 50% at 1200 mg, followed
by a steady increase to 96% at 2600 mg. Over 63% of the simulated trials select
the targeted dose, 500 mg, as the MTD. In each simulated trial, on average, over 20
patients were treated at this dose level.
In scenario 2, 1200 mg is the targeted dose level. Under this scenario, over 46% of
trials correctly select this dose level as the MTD. However, around 16%-17% of trials
select 1500 mg as the MTD, which is the adjacent higher dose level to the targeted
dose level of 1200 mg. However, just over 7 patients were treated at 1500 mg, whereas
more than twice (18 patients) this were treated per simulated trial at the targeted dose
level of 1200 mg.
Scenario 3 targets a dose level of 1500 mg. Probably or definitely related adverse
events have the highest toxicity probability (0.21) at the targeted dose level. Just under
60% of simulated trials select 1500 mg at the MTD. A dose level of 1200 mg is the
adjacent lower toxic dose level to the targeted MTD. Over 15% of trials select this
dose level as the MTD. About 20 patients per trial were treated at 1500 mg, whereas
only 10 patients per trial were treated at the adjacent lower dose level of 1200 mg.
Scenario 4 targets 2000 mg, in which Pr(U = 1|V = 1) slowly increases to 11%
at 1500 mg, followed by a doubling at 2000 mg and with a steady increase to 49% at
2600 mg. The toxicity probability of probably or definitely related adverse events has
a similar pattern. Around 47% of simulated trials select the targeted dose as the MTD.
At this dose level, about 17 patients per trial were treated. The adjacent lower dose
level of 1500 mg was selected in 20% of trials, in which just 8 patients per trial were
treated.
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Scenarios 5 and 6 have target dose levels of 2400 mg and 2600 mg respectively.
In these two scenarios Bin-Aerd-CRM selects the adjacent lower dose levels with a
similar probability as the target dose levels. Scenario 5 selects 2000 mg and 2400 mg
in just over 28% of trials. More patients (13) were treated at 2000 mg than at the
target dose level of 2400 mg. In scenario 6, the adjacent lower dose level to the target
dose is selected in just over 27% of trials, whereas over 25% of trials select the target
dose level. These two scenarios show that if low dose levels are ineffective and the
true MTD is at the upper end of high dose levels then it is highly likely that the design
would select an adjacent lower dose level of the true MTD.
The stopping rule and the safety constraint stopped less than 5% of trials in sce-
narios 3, 4, 5 and 6. In scenarios 1 and 2, about 15% and over 20% trials are stopped
early respectively. These scenarios target third and fourth dose levels respectively, and
therefore, due to the safety constraint, more trials were stopped early.
The scenarios presented above demonstrate that adverse event relatedness incor-
porated into the design methodology with a binary toxicity outcome often correctly
selects the targeted dose level. The design’s performance could be increased if prob-
ably or definitely related adverse events are incorporated in an ordinal fashion. Sec-
tion 3.3 presents Aerd-CRM, which includes ordinal toxicity outcome in the design
methodology.
3.3 Adverse Event Relatedness CRM
3.3.1 Prior Data
Figure 3.2 shows prior data for Aerd-CRM. Severity of an adverse event is observed
on an ordinal scale of 1 to 4, where adverse event scores of 1 to 4 correspond to mild,
moderate, severe and life-threatening adverse events, respectively. The prior data for
adverse events relating to a 200 mg yield 75% mild, 20% moderate, 4% severe and 1%
life-threatening adverse events. Similarly, 3000 mg yields 5% mild, 10% moderate,
35% severe and 50% life-threatening adverse events. It is assumed that 35% of adverse
events are doubtfully or possibly and 65% are probably or definitely related to the IND.
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Figure 3.2: Prior data for Aerd-CRM
3.3.2 Dose Toxicity Model
Adverse events doubtfully or possibly related to the IND are modelled using a two
parameter logistic model with an additive ‘clinical parameter’ p. These adverse events
are vaguely related to the IND and, therefore, detailed adverse event severity infor-
mation is superfluous. Doubtfully or possibly related adverse events which are life-
threatening are considered as dose-limiting. Probably or definitely related adverse
events are closely associated with the IND. Low grade toxicities of these adverse
events can still impact dose-escalation. Incorporating severity of these adverse events
into the dose-toxicity model will bring forth more information about low and high
grade toxicities. Adverse events probably or definitely related to the IND are modelled
using the cumulative logistic model shown in equation (3.5).
Pr(T = 4|R = 1, di) = p+
(
exp(αt + βtdi)
1 + exp(αt + βtdi)
)
× (1− p) (3.4)
Pr(T ≥ jt|R = 2, di) = exp(γtjt + δtdi)
1 + exp(γtjt + δtdi)
, jt = 2, 3, 4. (3.5)
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The Aerd-CRM identifies life-threatening adverse events which are doubtfully or
possibly, and probably or definitely related to the IND, and severe adverse events
which are probably or definitely related to the IND as DLT (shaded cells in Figure
3.2).
3.3.3 Dose Selection Criterion
Inequality (3.6) shows that the maximum of the estimated toxicity probabilities of
doubtfully or possibly, and probably or definitely, related adverse events are used to
select a dose level. The dose level with maximum toxicity probability closest to the
target toxicity probability is selected. Instead of the maximum a weighted average or
a linear combination of the two estimated probabilities could be used. However, the
maximum criterion provides a conservative solution in selecting dose levels when the
proportion of doubtfully or possibly, and probably or definitely related adverse events
of the IND for each dose level is unknown.
Dose dl is selected if and only if,
|max{Pr(T = 4|R = 1, dl),Pr(T ≥ 3|R = 2, dl)} − φt|
< |max{Pr(T = 4|R = 1, di),Pr(T ≥ 3|R = 2, di)} − φt|,
i = 1, . . . , K, di 6= dl. (3.6)
3.3.4 A Simulation Study for Aerd-CRM
This section discusses a simulation study which analyses the characteristics of the
Aerd-CRM. A dose level for the first cohort of patients is estimated based on the
prior data specified in Section 3.3.1. Models (3.4) and (3.5) fitted to the prior data
are shown in Figure 3.3, with the probabilities taken as data. The maximums of the
estimated toxicity probabilities, Pr(T = 4|R = 1) and Pr(T ≥ 3|R = 2), for each
dose level are shown as solid circles. The safety constraint discussed in Section 2.7.3
is implemented with st = 10%. This means that if the estimated toxicity at the starting
dose level is 10% higher than the target DLT then the adjacent lower dose level is
selected as the starting dose. Dose 1200 mg is selected as the starting dose using the
dose selection criterion shown in inequality (3.6). This dose level is the starting dose
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for every simulated trial in this section.
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Figure 3.3: Prior data fit for Aerd-CRM
Six scenarios created for the purpose of simulation represent the true toxicity
probabilities of each dose level. Ten thousand trials are simulated under each sce-
nario. Each trial was conducted with the safety constraint and the safety stopping rule
explained in Section 2.7.3. Values given for ct and st are 10% and 75% respectively.
This means that if the estimated toxicity of a selected dose level is 10% higher than
the target toxicity probability then the adjacent lower dose level is selected for the
following cohort of patients. The trial will stop whenever the recorded adverse event
is greater than 75%.
Figure 3.4 shows six scenarios set for Aerd-CRM simulation. Scenario 7 in the
top left panel targets 500 mg as the MTD. In this scenario, the toxicity probability
of adverse events doubtfully or possibly related to the IND is higher in the first two
dose levels than probable or doubtful adverse events. Scenario 8 in the right top panel
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targets 1200 mg as the MTD in which adverse events doubtfully or possibly related
to the IND play the key role in estimating the targeted MTD. The graph in the middle
left panel shows scenario 9, which targets 1500 mg as the MTD. This scenario is set
with the toxicity probability of adverse events probably or definitely related to the IND
being lower than adverse events doubtfully or possibly related to the IND in the first
four dose levels, and the converse is true in last four dose levels. Scenario 10 is set
to observe the properties of Aerd-CRM in selecting a high toxic dose level (2000 mg)
as the MTD. Scenario 11, which targets 2400 mg, is created such that first five dose
levels have low toxic probabilities. Scenario 12 is created such that all dose levels
have toxic probabilities less than the target toxicity probability. Scenarios 11 and 12
are created to observe the characteristics of Aerd-CRM whenever some or all of the
selected dose levels are ineffective.
Ten thousand trials under each scenario analyse characteristics of Aerd-CRM.
Every trial in each scenario begins with the same starting dose, and is subject to
the safety constraint and stopping rule discussed in Section 2.7.3. In addition, trials
with Bin-CRM in Section 2.7.4 and Ord-CRM in Section 2.7.5 are simulated for each
scenario, using the data simulated for Aerd-CRM. This brings forth the importance
of incorporating adverse event relatedness into the CRM. The Ord-CRM and the
Bin-CRM ignore adverse event relatedness to the IND, which implies that the data
simulated for Aerd-CRM should be combined by ignoring the relatedness score. For
Ord-CRM, simulated life-threatening adverse events which are doubtfully or possibly
related to the IND were recoded as severe adverse events. All other doubtfully or
possibly related adverse events were recoded as mild adverse events. Similarly, a
dose-limiting toxicity in Aerd-CRM (shaded cells in the grids of Figure 3.2) is treated
as dose-limiting in Bin-CRM. Therefore, the DLT criterion in Aerd-CRM is identical
to both Ord-CRM and Bin-CRM, which allows comparison.
Since the Ord-CRM and the Bin-CRM ignore adverse event relatedness to the
IND in each scenario, the targeted MTD of those designs may be higher than the
targeted MTD of Aerd-CRM. Sensitivity of scenario MTD to adverse event related-
ness (Pr(R = 1) and Pr(R = 2)) can be determined using inequality (3.7). Let
T˜ ∈ {1, . . . , 4} be the adverse event score of Ord-CRM. Inequality (3.6), which
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selects dose dl for the following cohort of patients in the Ord-CRM, will become
|Pr(T˜ ≥ 3|dl)− φt| < |Pr(T˜ ≥ 3|di)− φt|, i = 1, . . . , K, di 6= dl, (3.7)
Pr(T˜ ≥ 3|di) = Pr(T ≥ 3|R = 2, di)× Pr(R = 2)
+ Pr(T ≥ 4|R = 1, di)× Pr(R = 1).
Because inequality (3.7) is averaged over R, the toxicity probability of dose levels
are lower than those calculated in Aerd-CRM using inequality (3.6). However, toxicity
probability of the targeted MTD calculated using both inequality (3.6) and inequality
(3.7) are closer to the target toxicity probability for each scenario shown in this chap-
ter. That is, the target MTD of each scenario for Aerd-CRM and Ord-CRM remains
unchanged. Similarly, the target MTD for Bin-CRM and Aerd-CRM is identical for
those scenarios shown in this chapter.
3.3. AERD-CRM 53
0.0
0.2
0.4
0.6
0.8
1.0
Dose
Pr
ob
ab
ilit
y
50 15
0
50
0
12
00
15
00
20
00
24
00
26
00
ll
l
l
l
l
l l
Pr ( U >= 2 | V = 2 )
Pr ( U >= 3 | V = 2 )
Pr ( U >= 4 | V = 2 )
Pr ( U = 4 | V = 1 )
Scenario 7: MTD = 500
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Scenario 8: MTD = 1200
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Scenario 9: MTD = 1500
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Scenario 10: MTD = 2000
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Scenario 11: MTD = 2400
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Scenario 12: MTD = 2600
Figure 3.4: Aerd-CRM scenarios
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Table 3.2 shows the percent selecting a dose level as the MTD, based on 10000
simulated trials. The percent that the targeted MTD being selected is shown in bold
numbers. Scenario 7 targets a dose level of 500 mg as the MTD. Over 65% of
simulated Aerd-CRM trials correctly select this dose level as the MTD compared
to less than 20% of Bin-CRM and Ord-CRM trials. Additionally, under scenario 7,
Bin-CRM and Ord-CRM incorrectly select does levels higher than the targeted MTD
more often than Aerd-CRM. Doses of 1500 mg and 2000 mg are highly toxic doses
(probability of toxicity > 60%, Figure 3.4). In scenario 7, Bin-CRM and Ord-CRM
incorrectly select 1500 mg as the MTD in over 30% of trials compared to less than
1% for Aerd-CRM. These results suggest that designs which ignore adverse event
relatedness under scenario 7 circumstances select a higher MTD, putting patients at a
higher risk.
In scenario 8, 1200 mg is the targeted dose level. Under this scenario, over 69%
of Aerd-CRM trials correctly select this dose level as the MTD compared to less than
30% of Bin-CRM and Ord-CRM trials. As with scenario 7, Bin-CRM and Ord-CRM
incorrectly select dose levels higher than the targeted MTD more often than Aerd-
CRM, indicating that Aerd- CRM is, again, the superior design and is more effective
in minimising patient risk. However, under scenario 8, around 11%-12% of Aerd-
CRM trials select 500 mg as the MTD, which is below the targeted dose level of 1200
mg, compared to less than 1% of Bin-CRM and Ord-CRM trials. This suggests that
Aerd-CRM may be too risk-averse in a small percentage of trials.
Scenario 9 targets a high toxic dose level of 1500 mg as the MTD. Under this
scenario, Ord-CRM outperforms Aerd-CRM. Over 70% of Ord-CRM trials correctly
select 1500 mg as the MTD compared to over 60% of Aerd-CRM trials. Because the
toxicity probability of the next higher dose level of 2000 mg is extremely high (90%
probability of toxicity, Figure 3.4), Ord-CRM selects the adjacent lower dose level of
1500 mg, which is the targeted MTD, more often. However, Bin-CRM still selects
2000 mg as the MTD in over 55% trials. The toxicity probability of the targeted MTD
for this scenario is 0.31. Since it is higher than the target toxicity probability of 0.25,
Aerd-CRM selects the next lower dose level of 1200 mg as the MTD more often than
Bin-CRM and Ord-CRM.
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Scenario 10 targets 2000 mg, which has toxicity probability of 0.33 (Figure 3.4),
as the MTD. Over 47% of Aerd-CRM trials select this dose level as the MTD. A dose
level of 1500 mg is the adjacent lower toxic dose level to the targeted MTD. Over 35%
of Aerd-CRM trials select this dose level as the MTD, compared to less than 5% for
Bin-CRM and Ord-CRM. This indicates that Bin-CRM and Ord-CRM designs are not
as conservative as Aerd-CRM in selecting the adjacent lower dose level to the targeted
MTD. Once again, Ord-CRM outperforms Aerd-CRM in selecting the targeted dose
level. However, over 12% of Ord-CRM trials selects the higher toxic adjacent dose of
2400 mg, compared to less than 1% of Aerd-CRM trials.
In scenario 11, the first five dose levels have low toxic probabilities. This scenario
observes the characteristics of Aerd-CRM whenever the selected low dose levels are
ineffective. About 50% of Aerd-CRM trials stop early, over 22% select the targeted
dose level of 2400 mg, and over 19% of trials select the adjacent higher toxic dose
level of 2600 mg. The Ord-CRM shows similar behaviour in selecting the targeted
dose level of 2400 mg. However, over 35% of Ord-CRM trials select the adjacent
higher toxic dose level of 2600 mg, compared to over 50% Bin-CRM trials.
Scenario 12 is set with low toxic dose level. Since the dose-toxicity relationship
is monotonically increasing, the target dose is the last dose level of 2600 mg. It is
unfortunate to have all test dose levels with toxicity probability less than the target
toxicity probability. However, the majority of Aerd-CRM trials select the highest
toxic dose levels. Under this scenario both Ord-CRM and Bin-CRM behave similarly
in selecting the highest toxic dose level of 2600 mg.
This simulation study was carried out with the prior data shown in section 3.3.1
and the weighting scheme shown in section 2.7.2. Although, different prior data and
weighting schemes would yield different MTD estimation, comparing prior data and
weighting scheme effect is not the objective of this chapter. In conducting a real trial,
once the prior data is obtained, an appropriate weight for prior data can be obtained
by conducting a simulation study under different weighting schemes.
In this simulation study early stopping may occur due to the safety constraint and
safety stopping rule discussed in Section 2.7.3. In scenario 7, over 12% of trials
stopped early. Over 40% of trials stopped early in scenarios 11 and 12. In scenarios
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11 and 12, many dose levels are ineffective, so that over 40% of trials stopped early.
Overall, Table 3.2 shows that Aerd-CRM trials select the targeted MTD more often,
whereas both Ord-CRM and Bin-CRM more often select highly toxic dose levels. As
shown in scenarios 9 and 10, if the adjacent higher toxic dose level is extremely toxic
then Ord-CRM outperforms Aerd-CRM.
3.4 Aerd-CRM Discussion
An untoward occurrence of an adverse adverse event during a clinical investi-
gation cannot always be associated with the IND. However, a close-ended decision
on adverse event relatedness ignores the doubtful or possible relatedness. In current
practice, if an adverse event cause mystifies clinical investigators then it is sometimes
ignored. Ignoring such adverse event would result in treating patients at higher toxic
dose levels and a highly toxic MTD estimation. If such an adverse event is not ignored
then it is equivalent to an adverse event which has a definite relationship to the IND.
In this case, patients will be treated at low inefficient dose levels and the estimated
MTD will be futile. The Aerd-CRM provides a solution, adverse events doubtfully
or possibly related are included in the trial with an additive probability mass. In
addition, additional severity information on probably or definitely related adverse
events, included in the design methodology, plays a key role in dose estimation.
The Aerd-CRM extends the so called continual reassessment dose-finding design
methodology to the next level. It improves dose estimation by categorising adverse
event relatedness into two, ‘doubtfully or possibly related’ and ‘possibly or probably
related’. If a dose-finding trial is designed using Aerd-CRM then the relationship
of adverse events should be categorised. This means that patients who participate in
the trial get treated based on drug-related adverse events. The decision on adverse-
event relatedness rests on the clinical judgement of different clinicians. Therefore, the
Aerd-CRM is guaranteed to produce differences in dose estimation based on clinical
judgement. The Aerd-CRM concept can be extended to estimate an optimum biolog-
ical dose (OBD) in bivariate dose-finding designs. However, the pragmatic CRM has
not yet been extended for bivariate dose-finding clinical trials. Chapter 4 extends the
pragmatic CRM for bivariate dose-finding clinical trials.
Chapter 4
Global Cross-Ratio Continual Reassessment
Method
Synopsis
This chapter uses the global cross-ratio (GCR) model introduced by Dale (1986)
with the pragmatic version of the continual reassessment method described in Chap-
ter 2. This novel dose-finding design methodology is based on bivariate toxicity and
efficacy outcomes. It attempts to locate the optimum biological dose (OBD), that is,
the dose with maximum desirable efficacy for which toxicity is close to a pre-specified
threshold. Section 4.1 presents the binary global cross-ratio continual reassessment
method (Bin-GCR-CRM) in which toxicity and efficacy are observed as binary out-
comes. Section 4.2 presents the ordinal global cross-ratio continual reassessment
method (Ord-GCR-CRM), which incorporates ordered toxicity and efficacy outcomes
into the CRM.
The global cross-ratio is an appropriate measure of association for discrete, or-
dered responses (Dale, 1986, Molenberghs and Lesaffre, 1994). The design method-
ology presented in this chapter uses the global cross-ratio to measure the association
between toxicity and efficacy. However, in practice, efficacy outcomes are late-onset.
That is, a dose level cannot be estimated until the efficacy outcome of the current
cohort of patients is known. To overcome this problem, the expectation maximisation
(EM) algorithm is incorporated into the GCR-CRM and tackles this issue efficiently
(Dempster et al., 1977).
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Two simulation studies presented in this chapter reflect the late onset efficacy
outcomes. For example, the toxicity and efficacy endpoints are set to be four and
ten time intervals, respectively. Patients are enrolled after every five time intervals.
Efficacy outcomes for a cohort of patients are available whenever second adjacent
cohort of patients is enrolled in the trial. Until efficacy outcomes are observed, the EM
algorithm is used to predict them and to estimate a dose level for the next cohort of
patients. The pragmatic version of the GCR-CRM design is compared with a superior
version of the design in which toxicity and efficacy outcomes are made available
before the following cohorts of patients are enrolled.
4.1 Binary Global Cross-Ratio Continual Reassessment Method
This section presents the binary version of the GCR-CRM, in which toxicity and
efficacy are measured as binary outcomes. A binary toxicity outcome means either
dose-limiting toxicity (DLT) or not. Similarly, a binary efficacy outcome means either
desired efficacy (DE) or not.
Consider a dose-finding design with K test dose levels and cohort size n. It is as-
sumed that toxicity probability has a monotonically increasing relationship with dose.
The two-parameter logistic model in equation (4.1) below describes this relationship.
The intercept parameter αt represents the baseline toxicity probability when the dose
is zero. The slope parameter βt represents the change in toxicity probability that would
result from a unit change in dose.
The relationship between dose and efficacy is more complex than the dose-toxicity
relationship. It can be either monotone increasing or monotone decreasing, depending
on the test dose range and the IND. It is assumed that the efficacy probability increases
with dose until a critical high dose is reached after which the efficacy probability
decreases. The model in equation (4.2) satisfies such a dose-efficacy paradigm.
Equation (4.3) shows that the interaction between toxicity and efficacy is modelled
using a log cross-ratio.
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p
(i)
t = Pr(T = 1|di) =
exp(αt + βtdi)
1 + exp(αt + βtdi)
, (4.1)
p(i)e = Pr(E = 1|di) =
exp(αe − βe|di − d100e |)
1 + exp(αe − βe|di − d100e |)
, (4.2)
ψdi =exp(βte di) (4.3)
where d100e ∈ {d1, . . . , dK} is the dose associated with maximum desired efficacy.
The highest efficacious dose, d100e is estimated as explained in Section 4.1.1. The
cross-ratio ψdi is given by,
ψdi =
Pr(T = 0, E = 0|di) Pr(T = 1, E = 1|di)
Pr(T = 0, E = 1|di) Pr(T = 1, E = 0|di) . (4.4)
Equation (4.4) is expressed, alternatively, in terms of the marginal probabilities
p
(i)
t and p
(i)
e , as
ψdi =
[1− p(i)t − p(i)e + C(p(i)t , p(i)e ;ψdi)]C(p(i)t , p(i)e ;ψdi)
[p
(i)
e − C(p(i)t , p(i)e ;ψdi)][p(i)t − C(p(i)t , p(i)e ;ψdi)]
, (4.5)
where the bivariate distribution C(p(i)t , p
(i)
e ;ψdi) with association parameter ψdi is
given by,
C(p
(i)
t , p
(i)
e ;ψdi)
= Pr(T = 1, E = 1|di)
=
[1 + (ψdi − 1)(p(i)t + p(i)e )]−
√
[1 + (ψdi − 1)(p(i)t + p(i)e )]2 − 4ψdi(ψdi − 1)p(i)t p(i)e
2(ψdi − 1)
.
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4.1.1 Likelihood and Parameter Estimation
Figure 4.1 (a) below shows a two-way table of complete observations after enrolling
a cohort of patients to receive dose level dk (k = 1 . . . K), where njtje is the number
of patients with toxicity jt and efficacy je (jt, je = {0, 1}). The dependence on dose
dk is dropped from the notation temporarily, omitting the superscript (k). Therefore,
the number of patients enrolled to receive dose level dk is given by, n =
1∑
jt=0
1∑
je=0
njtje .
The joint toxicity-efficacy probabilities are given by, pjtje = Pr(T = jt, E = je).
Efficacy (E)0 1
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 (T
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0
1
(a)  Toxicity and Efficacy Observed
n00
n10
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n11
p00
p10
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p11
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n0+
n1+
1 − pt
pt
(b)  Efficacy Missing
Figure 4.1: (a) complete outcomes and (b) classification of complete
outcomes into incompletely unobserved efficacy data
Figure 4.1 (b) shows incomplete observations after the toxicity endpoint. Re-
introducing dependence on dose dk notation, the number of patients who experienced
toxicity is given by, n(k)1+ = n
(k)
10 + n
(k)
11 . The marginal toxicity probability p
(k)
t is given
by equation (4.1) and the marginal likelihood is shown in (4.6).
l(αt, βt|n(k)1+, d1:K) =
K∏
k=1
[
p
(k)
t
]n(k)1+ × [1− p(k)t ]n(k)−n(k)1+ . (4.6)
The efficacy endpoint is long and, therefore, the number of patients with DE is
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unknown at the time of enrolling the next cohort of patients. The marginal efficacy
probability and the global cross-ratio for the next cohort of patients are, thus, estimated
using the EM algorithm.
The distribution of n(k)jt1, the number of patients with DE, is given by,
n
(k)
jt1
| n(k)jt+ ∼ Bin
(
n
(k)
jt+
,
p
(k)
jt1
p
(k)
jt0
+ p
(k)
jt1
)
; (4.7)
where ‘+’ denotes summing over the subscript it replaces. The numerator of the
Binomial probability p(k)jt1 is unknown for jt = {0, 1}, where as p(k)jt0 + p(k)jt1 = p(k)t is
inferred from the likelihood (4.6).
EM Algorithm
1. Initial Step
An initial value for each parameter is estimated from patients already entered
into the trial. For the first cohort of patients, initial parameter values are esti-
mated from prior data. Section 4.1.3 explains the prior data.
2. Expectation Step
E(n(k)11 |n(k)1+, p(k)t ) =
p
(k)
11 n
(k)
1+
p
(k)
t
E(n(k)01 |n(k)0+, p(k)t ) =
p
(k)
01 n
(k)
0+
1− p(k)t
3. Maximisation Step
• The marginal efficacy probability p(k)e is estimated using the profile likeli-
hood of d100e , profiling out the parameters αe and βe.
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– The marginal likelihood,
l(αe, βe, d
100
e |n(k)+1, d1:K) =
K∏
k=1
[
p(k)e
]n(k)+1
× [1− p(k)e ]n(k)−n(k)+1 , (4.8)
is used to estimate the baseline parameters αe and βe, for fixed d100e .
– Let αˆe(d100e ) and βˆe(d100e ) be the estimates of αe and βe with fixed d100e
respectively. The profile likelihood, given by,
lp(d
100
e ) = l(αˆe(d
100
e ), βˆe(d
100
e ), d
100
e |n(k)+1, d1:K),
is used to estimate d100e .
• The cross-ratio ψdi is estimated using equation (4.3) and the full likelihood
given by,
l(βte|n(k)jtje , d1:K) =
K∏
k=1
1∏
jt=0
1∏
je=0
[
p
(k)
jtje
]n(k)jtje
. (4.9)
The expectation step and the maximisation steps alternate until convergence.
The converged parameter values are used to enrol the next cohort of patients.
As the trial progresses, efficacy outcomes estimated in the expectation step are
replaced by true outcomes.
4.1.2 Dose Selection Criterion
Bivariate dose-finding designs estimate an OBD by jointly evaluating toxicity and
efficacy. The OBD has the highest efficacy with tolerable toxicity. Therefore, there
is no so called target efficacy probability. The Bin-GCR-CRM selects dose levels
based on joint toxicity efficacy probability Pr(E = 1, T = 0), and marginal toxicity
probability Pr(T = 1).
Suppose φt is the toxicity probability cut-off. Dose level dl is administered to a
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cohort of patients if and only if, dl = min{dl1 , dl2} , where dl1 and dl2 are given by,
Pr(E = 1, T = 0|dl1) > Pr(E = 1, T = 0|di), i = 1, . . . , K, di 6= dl1 (4.10)
|Pr(T = 1|dl2)− φt| < |Pr(T = 1|di)− φt|, i = 1, . . . , K, di 6= dl2 . (4.11)
Similar to the original CRM, the Bin-GCR-CRM requires clinicians to specify a
toxicity cut-off. Dose level dl1 has maximum desired efficacy probability with no
toxicity. Dose level dl2 has marginal toxicity probability closest to the toxicity cut-off.
Toxicity has a monotonically increasing relationship with dose levels and, therefore,
the minimum of dl1 and dl2 is selected as the OBD. This criterion prioritises patients’
safety rather than curing disease.
4.1.3 A Simulation Study for Bin-GCR-CRM
A simulation study discussed in this section explores the design characteristics of Bin-
GCR-CRM. The number of test dose levels K is set to eight and the sample size N is
set to 64. The eight discrete dose levels used in this simulation are: 150 mg, 500 mg,
800 mg, 1200 mg, 1500 mg, 2000 mg, 2400 mg and 2600 mg. The toxicity cut-off φt
is set to 0.05.
This design methodology estimates a starting dose based on prior data. Similar
to the approach described in Chapter 3, clinicians’ elicited predicted DLT and DE
combinations are used as the data for prior data. For a real trial, information from
previously conducted trials, for drugs which are similar to the IND, should be reflected
in prior data. The Bin-GCR-CRM requires joint toxicity and efficacy outcomes of
d100e and, a low and a high dose level to estimate a starting dose. The prior data retain
the sequential nature of the trial whenever some toxicity and efficacy outcomes are
unobserved.
Figure 4.2 shows the prior data specified for this simulation study. A low and
a high dose level for which toxicity and efficacy outcomes are predictable must be
decided on. Here, Figure 4.2 (a) indicates that a dose level of 200 mg will produce
2% DLT and 20% DE outcomes. Figure 4.2 (c) indicates that a dose level of 3000 mg
will produce 40% DLT and 10% DE outcome.
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Figure 4.2: Prior data corresponding to (a) low toxic dose level, (b) highest
efficacious dose and (c) high toxic dose level for Bin-GCR-CRM
Additional information on the highest efficacious dose is vital for GCR-CRM.
Efficacy does not necessarily increase with dose levels. A wise choice for d100e is any
dose level between the low and high dose level whose toxicity and efficacy outcomes
are predictable. In a real trial, clinicians’ knowledge and information of drugs similar
to the IND are crucial to decide on d100e and its efficacy toxicity profile. In Figure 4.2
(b), 1200 mg is the highest efficacious dose. This dose level will produce 10% DLT
and 80% DE outcomes.
The joint probabilities Pr(T = 1, E = 1) and Pr(T = 0, E = 0) at the dose
levels for which prior information is predictable must be elicited. Figure 4.2 (a)
shows that a dose level of 200 mg will produce 78% non-toxic and non-efficacious
outcomes, and 0% DLT and DE outcomes. Figure 4.2 (b) shows that a dose level
of 1200 mg will produce 15% non-toxic and non-efficacious outcomes, and 5% DLT
and DE outcomes. Similarly, Figure 4.2 (c) indicates that 3000 mg will produce 60%
non-toxic and non-efficacious outcomes, and 10% DLT and DE outcomes.
Figure 4.3 shows models (4.1), (4.2) and (4.3) fitted to the prior data specified in
Figure 4.2. For each dose level, either estimated efficacy probability with no toxicity
Pr(E = 1, T = 0) or estimated toxicity probability, Pr(T = 1) is shown in solid
circles. The dose level 800 mg is the starting dose since it has the highest estimated
efficacy with marginal toxicity (0.047) less than the toxicity cut-off probability.
This simulation study implements the safety constraint and stopping rules dis-
cussed in Section 2.7.3. The safety constraint is set with ct = 5%, meaning the
4.1. BIN-GCR-CRM 67
0.0
0.2
0.4
0.6
0.8
1.0
Dose
Pr
ob
ab
ilit
y
15
0
50
0
80
0
12
00
15
00
20
00
24
00
26
00
l
l
l
l
l
l
l
l
Pr(T=1)
Pr(E=1)
Pr(E=1,T=0)
Figure 4.3: Fit of prior data for Bin-GCR-CRM. Prior data from
Figure 4.2 Models (4.1), (4.2), (4.3) fitted.
adjacent lower dose level of an estimated dose level is selected only if the estimated
toxicity at that dose level is over 5% higher than the toxicity probability cut-off. The
safety and efficacy stopping rule are set with st = 30% and sf = 10%, respectively.
4.1.3.1 Scenarios: Bin-GCR-CRM
Scenarios discussed in this section are created for the purpose of simulation. These
scenarios represent the true toxicity and efficacy probabilities. A plot of these sce-
narios is shown in Appendix B. During the trial, efficacy outcomes for a cohort of
patients are available whenever second adjacent cohort of patients is enrolled in the
trial. Until efficacy outcomes are made available, cell counts (Figure 4.1) are replaced
by expected counts. Those expected counts are later replaced by simulated efficacy
outcomes. Therefore, a dose level estimated for the adjacent cohort of patients would
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differ when using the simulated outcomes compared to expected outcomes. The data
simulated for the pragmatic trial were collected and a superior trial was simulated for
the same data in which the efficacy endpoint is made available before the following
cohort of patients is enrolled. The superior trial simulations do not require the EM
algorithm. A real trial can be designed using the pragmatic trial approach but the
superior trial is fictitious.
Table 4.1 shows the results of 1000 simulated pragmatic and superior Bin-GCR-
CRM trials. Under each scenario, the first two rows of the table represent the true
toxicity and efficacy probabilities respectively; the third row represents the selection
percentage of each dose level for the pragmatic trial; the fourth row shows (Pˆr(T =
1) > 0.10)%, which is the percentage of estimated toxicity probability greater than a
10% threshold (recall the toxicity cut-off is 5%); the fifth row is the estimated efficacy
probability less than a 20% threshold; the sixth row is the number of patients treated
at each dose; and the remaining rows 7-10 correspond to the results using superior
trials. The table also shows that the number of inconclusive trials (Stop), and the
simulated number of toxicities (No. Tox) and efficacies (No. Eff) averaged over 1000
simulations.
In scenario 1, the toxicity probability slightly increases to 11% at the dose level
of 800 mg, where it dramatically increases to 92% at the last dose level. The efficacy
probability is 10% at the lowest dose level. It increases fast to over 90% at the dose
level of 1500 mg, then decreases to just over 20% at the last dose level. This scenario
targets 500 mg, which has toxicity probability closest to the toxicity probability cut-
off. Both pragmatic and superior designs select the targeted MTD with the highest
percentage. This shows that the EM algorithm predicts missing efficacy outcomes
effectively. Over 22% of the superior trials select the adjacent lower dose level of 150
mg as the MTD. This percentage is slightly higher (25%) in pragmatic trials. Over
10% of pragmatic and superior trials selected the adjacent higher toxic dose level of
800 mg. The percentage of trials that stopped early is 35.3% in pragmatic trials, which
increased to 40.6% in superior trials.
Scenario 2 targets a dose level of 500 mg, which has the highest efficacy prob-
ability. The first three dose levels of this scenario have very low toxicity, but are
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highly efficacious and last three dose levels are extremely toxic and non-efficacious.
The targeted MTD is selected by over 50% of pragmatic Bin-GCR-CRM trials. This
percentage drops to 37.2% in superior trials. The estimated toxicity probability of
the targeted dose level greater than a threshold of 10% is similar under both designs.
The number of patients treated at the dose level of 500 mg is 19 in pragmatic trials
and slightly less (16) in superior trials. Under both trials no patients were treated at
the last three higher toxic dose levels. This scenario suggest that if the targeted dose
level is highly efficacious and has low toxicity then the Bin-GCR-CRM is effective in
selecting this dose level.
Scenario 3 targets a dose level of 800 mg. The first two dose levels of this scenario
have low toxicity and non-efficacious, and the last two dose levels are highly toxic
and non-efficacious. The targeted dose level is 20% efficacious with the true toxicity
probability equal to the toxicity probability cut-off. The targeted dose under both
pragmatic and superior designs is selected with the highest percentage of trials. The
percentage of trails selected for the targeted dose level is 15% in superior trials, which
is doubled in pragmatic trials. Note that the number of trials that stop early is two
times higher in superior trials than pragmatic trials. Over, 17% of pragmatic trials
select the adjacent higher toxic dose level of 1200 mg. This dose level is extremely
efficacious (90%). In this scenario, the toxicity probability cut-off plays a key role in
selecting the target dose level, and the Bin-GCR-CRM performs well in selecting the
targeted OBD.
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Scenario 4 targets a dose level of 1500 mg. The true toxicity probability of the
lowest dose level is zero, which slowly increases to 0.22 at the last dose level of
2600 mg. The true dose-efficacy relationship is monotone increasing. Over 45% of
pragmatic trials select the targeted dose level of 1500 mg. The highest number of
patients (24) was treated at this dose level. About 30% of pragmatic trials select the
adjacent lower dose level of 1200 mg. In this dose level, 21 patients are treated per
trial.
Note that the majority of superior trials stop early in scenarios 3 and 4. This
is because in these scenarios the starting dose is set with low efficacy probabilities
and, therefore, the simulated efficacy data was less than 10% (futility stopping rule).
However, higher efficacy outcomes are predicted using EM algorithm. This is not a
limitation of this design methodology. The futility stopping rule should be adjusted
when a few efficacy outcomes are expected at lower dose levels. For illustration
purpose this simulation study is set with same stopping rules for all scenarios.
The four scenarios set in this simulation study shows that the Bin-GCR-CRM often
correctly selects the targeted dose level. The designs performance could be increased
if severity of adverse events and the progress rate of disease are incorporated into the
design methodology. This is considered in the following section.
4.2 Ordinal Global Cross-Ratio Continual Reassessment Method
Dichotomised toxicity and efficacy endpoints may fail to accurately capture the
effect of the IND. The ordinal version of the GCR-CRM is presented in this section.
Suppose toxicity is observed on a 1 to 4 ordered scale, with adverse event scores of 1 to
4 being ‘mild’, ‘moderate’, ‘severe’ and ‘life-threatening’ adverse events, respectively.
Efficacy is observed on a 1 to 3 ordered scale, with efficacy scores of 1 to 3 being
‘progressive’, ‘stable’ and ‘remissive’ of a medical condition.
An approach similar to the Bin-GCR-CRM with cumulative logistic models (4.12)
and (4.13) below replacing model equations (4.1) and (4.2) respectively is sufficient
to handle bivariate ordinal outcomes. The marginal dose-toxicity and dose-efficacy
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models are given by,
Pr(T ≥ jt|di) = exp(γtjt + δtdi)
1 + exp(γtjt + δtdi)
, jt = 2, 3, 4. (4.12)
Pr(E ≥ je|di) = exp(γeje − δe|di − d
100
e |)
1 + exp(γeje − δe|di − d100e |)
, je = 2, 3. (4.13)
The toxicity-efficacy outcome and the corresponding cell probabilities for a given
dose level can be arranged in a 4x3 design grid as shown in Figure 4.4.
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Figure 4.4: Design grid for Ord-GCR-CRM
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The design grid can be dichotomized at (jt, je) to a 2x2 contingency table given
by,
{T ≤ jt, E ≤ je} {T ≤ jt, E > je}
{T > jt, E ≤ je} {T > jt, E > je}
, (4.14)
where, jt = 2, 3, 4 and je = 2, 3. The interaction between toxicity and efficacy is
modelled using the log cross-ratio, given by,
ψ(jt, je, di) = exp(γte di), (4.15)
where, the global cross-ratio ψ(jt, je, di) is given by,
ψ(jt, je, di) =
Pr(T ≤ jt, E ≤ je|di) Pr(T > jt, E > je|di)
Pr(T ≤ jt, E > je|di) Pr(T > jt, E ≤ je|di) . (4.16)
The design grid in Figure 4.4 can be dichotomised in six different ways. For each
dichotomisation, equation (4.5) holds with the association parameter ψdi replaced by
ψ(jt, je, di). Model (4.15) assumes that ψ(jt, je, di) does not depend on the dichotomi-
sation cut points (jt, je).
4.2.1 Estimation of Model Parameters
Parameter estimation is similar to Section 4.1.1. Once the toxicity endpoint is met,
marginal dose-toxicity model parameters, γt2, γt3, γt4 and δt are estimated using the
method of maximum likelihood estimation. Due to the long efficacy endpoint, missing
marginal dose-efficacy model parameters, γe2, γe3, δe and d100e are estimated using the
EM algorithm.
The distribution of cell counts in the design grid (Figure 4.4) with missing efficacy
data follows a Multinomial distribution given by,
n
(k)
jt1
, n
(k)
jt2
, n
(k)
jt3
| n(k)jt+ ∼ Multinomial
(
n
(k)
jt+
;
p
(k)
jt1
p
(k)
jt+
,
p
(k)
jt2
p
(k)
jt+
,
p
(k)
jt3
p
(k)
jt+
)
; (4.17)
where, jt = 1, 2, 3, 4 and ‘+’ denotes summing over the subscript it replaces.
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If n(k)jtje (jt = 1, . . . , 4 and je = 1, . . . , 3) is missing in the design grid (Figure 4.4)
then it is replaced by the expected value given by,
E(n(k)jtje|n(k)jt+) =
p
(k)
jtje
n
(k)
jt+
p
(k)
jt+
. (4.18)
The EM algorithm is applied until convergence of the model parameters (Section
4.1.1).
4.2.2 Dose Selection Criterion
Toxicity scores of 3 and 4 with efficacy score of 3 are considered as ‘dose-limiting’.
That is, severe and life-threatening adverse events with progressive disease are ‘dose-
limiting’.
The Ord-GCR-CRM selects dose levels based on joint toxicity-efficacy probability
Pr(E ≥ 2, T < 3), and marginal toxicity probability Pr(T ≥ 3).
Suppose φt is the toxicity probability cut-off. Dose level dl is administered to a
cohort of patients if and only if, dl = min{dl1 , dl2} , where dl1 and dl2 are given by,
Pr(E ≥ 2, T < 3|dl1) > Pr(E ≥ 2, T < 3|di), i = 1, . . . , K, di 6= dl1 , (4.19)
|Pr(T ≥ 3|dl2)− φt| < |Pr(T ≥ 3|di)− φt| i = 1, . . . , K, di 6= dl2 . (4.20)
Dose level dl1 has the maximum joint toxicity-efficacy probability for which the
‘stable or remissive’ medical condition persists with ‘mild or moderate’ adverse events.
Dose level dl2 has marginal probability of ‘severe or life-threatening’ adverse events
closest to the toxicity cut-off. The minimum of dl1 and dl2 is selected as the OBD.
4.2.3 A Simulation Study for Ord-GCR-CRM
A simulation study is set with sample size of 64 and cohort size of 4. Dose levels are
150 mg, 500 mg, 800mg, 1200 mg, 1500 mg, 2000 mg, 2400 mg and 2600 mg. The
toxicity cut-off is 0.05. Similar to the Bin-GCR-CRM approach, the prior data need
to be specified for a low dose, high dose and the dose with maximum efficacy (d100e ).
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Assume 200 mg, 3000 mg and 1200 mg are the low, high and d100e dose levels
with known toxicity-efficacy profile respectively. A dose level of 200 mg yields 75%
mild, 23% moderate, 1% severe and 1% life-threatening adverse events, and 80%
progressive, 15% stable and 5% remissive efficacy outcomes. A dose level of 3000 mg
yields 10% mild, 50% moderate, 15% severe and 25% life-threatening adverse events,
and 90% progressive, 8% stable and 2% remissive efficacy outcomes. Similarly, d100e
yields 55% mild, 35% moderate, 7% severe and 3% life-threatening adverse events,
and 20% progressive, 10% stable and 70% remissive efficacy outcomes.
Figure 4.5 shows the estimated marginal and joint, toxicity and efficacy probabil-
ities of the prior data. The marginal probability of toxicity greater or equal to severe
adverse events, Pr(T ≥ 3), is closest to 0.05 at 800 mg. The joint probability of
toxicity greater or equal to a stable medical condition with less than severe adverse
events, Pr(E ≥ 2, T < 3), is highest at 1200 mg. The minimum of these two doses,
800 mg, is the starting dose.
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Figure 4.5: Fit of prior data for Ord-GCR-CRM. Prior data and
Models (4.12), (4.13), (4.15) fitted.
4.2.3.1 Scenarios: Ord-GCR-CRM
Figure 4.6 shows six scenarios, which are set to analyse the operating characteristics of
Ord-GCR-CRM. These scenarios represent the true toxicity and efficacy probabilities.
Scenario 5, in the top left panel, targets 500 mg as the OBD. The toxicity cut-off plays
the key role in deciding the OBD. The efficacy probability is bell shaped with a peak
of over 0.6 at the dose level of 1500 mg. Scenario 6, in the top right panel, also targets
500 mg as the OBD. Here, the targeted OBD has the highest efficacy probability.
Scenario 7 in the mid left panel, targets a dose level of 800 mg. In this scenario, the
joint toxicity-efficacy probability of the lowest dose level is over 40%, where it slightly
increases to over 50% at 1500 mg and then drastically drops towards the largest dose
level. Scenario 8, in the mid right panel, targets the highest efficacious dose level of
800 mg. Scenarios 9 and 10 in the bottom panel are set with monotonic increasing
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dose-efficacy relationships. Scenario 9 targets a dose level of 1200 mg, which has
toxicity probability closest to the cut-off value. Scenario 10 targets a dose level of
1500 mg, which is the safest dose with highest efficacy.
The pragmatic and superior designs used in this simulation study have the same
explanation as in Section 4.1.3.1. That is, for pragmatic trials, efficacy outcomes
for a cohort of patients are available whenever the second adjacent cohort of patients
is enrolled in the trials and, therefore, cell counts are replaced by expected counts.
Those expected counts are later replaced by simulated efficacy outcomes. The data
simulated for the pragmatic trial were collected and a superior trial was simulated for
the same data in which the efficacy endpoint is made available before the following
cohort of patients is enrolled. In addition, for each scenario, pragmatic Bin-GCR-
CRM is simulated using the data simulated for pragmatic Ord-GCR-CRM. This will
bring forth the importance of incorporating severity of adverse events and progress rate
of efficacy into the GCR-CRM. The Bin-GCR-CRM ignores additional information on
toxicity and efficacy, which implies that the data simulated for Ord-GCR-CRM should
be combined by ignoring the severity and progress rate scores. Simulated severe and
life-threatening adverse events are recoded as DLT, and stable and remissive disease
conditions are recoded as DE outcome.
Table 4.2 shows the percent selecting a dose level out of 1000 simulated trials.
Scenario 5 targets a dose level of 500 mg as the OBD. Here, OBD is decided by
the toxicity probability cut-off value. Over 35% of pragmatic Ord-GCR-CRM trials
correctly select the targeted OBD. This percentage drops to 29.4 in the superior design
and to 19.1 in the Bin-GCR-CRM design. The percentage of trials that stop early is
19.7% in Ord-GCR-CRM trials, which increases to 26.4% in the superior design and
to 33.5 in the Bin-GCR-CRM design. The number of simulated DLT (No. Tox) and
DE (No. Eff) outcome per trial is similar in all three designs. This scenario shows that
Ord-GCR-CRM is good enough in selecting the targeted OBD, if it is determined by
a toxicity cut-off.
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Scenario 6 targets the highest efficacious dose level of 500 mg. The majority
of Ord-GCR-CRM trials (74.4%) select the targeted OBD, whereas only 23.0% of
superior design and 20.2% Bin-GCR-CRM trials select the dose level of 500 mg.
Over 25% of superior and Bin-GCR-CRM trials wrongly select the adjacent higher
toxic and low efficacious dose levels of 800 mg. A few (4.7%) pragmatic Ord-GCR-
CRM trials stop early. Under this scenario the pragmatic Ord-GCR-CRM performs
much better than the other two designs.
Scenario 7 targets a dose level of 800 mg. This dose level has toxicity probability
closest to the cut-off value. Here, 50.3% of pragmatic Ord-GCR-CRM trials correctly
select 800 mg as the OBD compared to around 43% of superior Ord-GCR-CRM
and only 29.9% of Bin-GCR-CRM trials. Most superior and Bin-GCR-CRM trials
select the adjacent lower and higher toxic dose levels. The number of DLTs and DEs
simulated for all three trials does not vary by a large amount. The percentage of trials
that stop early is 4.8% in pragmatic Ord-GCR-CRM trials, which slightly increases to
7.7% in superior Ord-GCR-CRM trials and is three times higher in Bin-GCR-CRM
trials.
Scenario 8 targets a highest efficacious dose level of 800 mg. Just over 63% of
pragmatic Ord-GCR-CRM trials correctly select 800 mg as the OBD, whereas only
48.5% of superior Ord-GCR-CRM and 32.3% of Bin-GCR-CRM trials select this dose
level as the OBD. Note that 25% of superior Ord-GCR-CRM trials and over 30% of
Bin-GCR-CRM trials select the adjacent higher toxic dose level of 1200 mg. This dose
level is less efficacious than the targeted OBD. Again, in this scenario the pragmatic
Ord-GCR-CRM is prove to be more effective than Bin-GCR-CRM.
Scenario 9 targets a dose level of 1200 mg. This scenario assumes a monotonically
increasing dose-efficacy relationship. The targeted OBD has true toxicity probability
closest to the cut-off value and true efficacy probability greater than 0.35. Over 45%
of pragmatic Ord-GCR-CRM trials select 1200 mg as the OBD, whereas only 35.6%
of superior Ord-GCR-CRM trials and 35.1% Bin-GCR-CRM trials select the targeted
OBD. In all three designs, over 27% of trials select the adjacent lower dose level of
800 mg. This is because the targeted OBD is set with true toxicity probability slightly
greater than the toxicity cut-off value of 0.05. This scenario shows that the pragmatic
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Ord-GCR-CRM is satisfactory in selecting the correct OBD when the dose-efficacy
relationship is monotone increasing.
Scenario 10 is set with a monotonically increasing dose-efficacy relationship. The
targeted OBD of 1500 mg has true toxicity probability closest to the toxicity cut-off
and true efficacy probability greater than 0.4. Over 45% of pragmatic Ord-GCR-CRM
trials select the adjacent lower toxic dose level. This scenario shows that Ord-GCR-
CRM may be risk averse whenever a monotonic dose-efficacy relationship is assumed.
If the true efficacy probabilities of dose levels increase monotonically, then the dose
selection criterion depends only on the toxicity cut-off. The majority of the trials
select adjacent lower dose levels due to the safety constraint. In this scenario, the
majority of superior Ord-GCR-CRM trials stop early. This is because the starting
dose of this scenario is set with low efficacy probabilities and, therefore, the simulated
efficacy data was less than futility stopping rule (See the detail explanation in Section
4.1.3.1 for Scenarios 3 and 4). The Bin-GCR-CRM still under performs compared to
Ord-GCR-CRM.
In conclusion, this chapter presents a newly developed bivariate dose-finding de-
sign methodology. This methodology uses the global cross-ratio model, which is a
flexible parametric structure that accounts for marginal dose-toxicity, dose-efficacy
relationships, and the toxicity-efficacy interaction. The GCR-CRM uses a flexible
parametric model that accounts for monotone increasing, monotone decreasing, or
unimodal dose-efficacy relationships. Late onset efficacy outcomes are predicted us-
ing the EM algorithm, which uses the available toxicity outcomes and the dependency
structure between toxicity and efficacy. The dose selection is made using the joint
toxicity-efficacy and marginal toxicity probabilities. A binary and an ordinal version
of the design methodology are described in this chapter. Two simulations studies
show that GCR-CRM has good operating characteristic in selecting the appropriate
OBD. The global cross-ratio model used in this design methodology can also be
used to predict the interaction effect between drugs. Chapter 5 develops a novel drug
combination design methodology using the global cross-ratio model.
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Chapter 5
Global Cross-Ratio Continual Reassessment
Method for Combined Drugs
Synopsis
This chapter presents a novel CRM type design methodology to identify the safety
profile of a drug combination. The initial form of this novel methodology is described
for phase I drug combination trials with two drugs. This design methodology uses
two-parameter logistic models to estimate the latent marginal toxicity effects of each
drug (Section 2.7.1). Adverse events caused by both drugs can be observed in counts
using a latent contingency table. Therefore, the cross-ratio can be directly estimated
using the four quadrants of the contingency table. The Plackett distribution is the
natural choice to estimate the interaction effect (Plackett, 1965). The bivariate cross-
ratio model first introduced by Dale (1986) is used with the Plackett distribution to
model the bivariate categorical toxicity variables. The number of toxic events caused
by individual drugs cannot be observed, and therefore, the Expectation-Maximisation
(EM) algorithm is used to predict the unobserved marginal toxicity outcome (Demp-
ster et al., 1977). The global cross-ratio continual reassessment method for combined
drugs (GCR-CRM for CD) is an extension of the pragmatic version of the CRM
discussed in Section 2.7.
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5.1 Phase I Drug Combination Trials
Development of single drugs sometimes fails to deliver satisfactory results. Con-
current development of more than one drug creates opportunities to increase the ther-
apeutic effect and reduce the adverse events. These INDs are individually tested for
safety on human beings. The joint toxic effect of the INDs is complex. Studying the
mechanisms which lead to the joint action requires an appropriate statistical model
and the distribution of the joint effects.
Simultaneous administering of drugs produces joint treatment effects. The interac-
tion of multiple drugs may target a single disease, multiple diseases or a single disease
with related pathways. The marginal effect of concurrently administered doses of each
drug is unobservable because doses of the INDs are administered simultaneously. The
composite joint interaction effect of the combination and the latent marginal effects of
the individual drugs can be used to track the adverse effect of a drug combination.
Generally, the dose-toxicity relationship of an individual IND is monotone increas-
ing. The relationship between combined doses and the joint toxicity effect is unknown.
This makes it difficult to order the dose combinations in a monotonically increasing
fashion. Ordering dose combinations based on estimated toxicity probabilities does
not accurately estimate the optimum dose because of drug-drug interaction. The
challenge in drug combination trials in toxicity only trials is estimating the MTD
combinations with small sample sizes. Section 5.2 considers the situation of binary
toxic response variable under the assumption of a monotonically increasing relation-
ship between dose and marginal toxicity. Section 5.3 considers the severity of toxic
response variable with the same marginal assumption.
5.2 Binary Global Cross-Ratio Continual Reassessment Method
for Combined Drugs
This section presents the binary version of the GCR-CRM for combined drugs
(Bin-GCR-CRM for CD), in which an adverse event is measured as a binary outcome.
A binary toxicity outcome means either dose-limiting toxicity (DLT) is observed or
not after administering a dose combination.
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Suppose I dose levels of drug A (da1 , . . . , daI ) and J dose levels of drug B
(db1 , . . . , dbJ ) are selected to jointly evaluate the toxicity effect, and the dose combi-
nation (dai , dbj) is administered to a cohort of n patients. After the toxicity end point,
the number of patients with toxic outcomes is known. However, the drug that caused
the toxicity is unknown.
Figure 5.1: (a) complete outcomes and (b) latent or unobserved
outcomes for Bin-GCR-CRM for combined drugs
Figure 5.1 (a) shows the observed outcomes after the toxicity end point. The
number of patients with no toxicity, n00, and number of patients with toxicity, n−n00,
are the observed outcomes. Figure 5.1 (b) shows the latent or unobserved toxicity
profile of the combined drugs. The number of patients with adverse events caused by
drug B but not drug A (n01), drug A but not drug B (n10) and both drugs A and B (n11)
are unknown (n− n00 = n01 + n10 + n11).
The latent marginal dose-toxicity relationships of drugs A and B are modelled
using the two parameter logistic models in equations (5.1) and (5.2) respectively.
Intercept parameters αa and αb represent the baseline toxicity probability estimate
when the dose of drug A or drug B is zero respectively. Slope parameters βa and βb
represent the change in toxicity probability that would result from a unit change in
dose of drug A and drug B respectively.
The joint toxicity effect of simultaneously administered drugs has no definite
structure. Since toxicity is observed as a discrete outcome, the global cross-ratio
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between latent binary toxicity outcomes can be used to estimate the joint effect (Dale,
1986).
Equation (5.3) shows that the drug-drug interaction is modelled using a log cross-
ratio. The association parameter γab can be estimated, which implies the global cross-
ratio is estimated at each dose combination dk. In this equation, dose levels of drug A
and drug B are multiplicative on the scale of ψ.
p(i)a = Pr(Ta = 1|dai) =
exp(αa + βadai)
1 + exp(αa + βadai)
, (5.1)
p
(j)
b = Pr(Tb = 1|dbj) =
exp(αb + βbdbj)
1 + exp(αb + βbdbj)
, (5.2)
ψdk = exp(γab dk), (5.3)
where, dk = dai + dbj , k = 1, . . . , K ,K = I × J , and the interaction term, ψdk ,
which is the global cross-ratio, is given by,
ψdk =
Pr(Ta = 0, Tb = 0|dk) Pr(Ta = 1, Tb = 1|dk)
Pr(Ta = 0, Tb = 1|dk) Pr(Ta = 1, Tb = 0|dk) . (5.4)
Equation (5.4) is expressed, alternatively, in terms of the marginal probabilities pa
and pb, as
[1− p(i)a − p(j)b + C(p(i)a , p(j)b ;ψdk)]C(p(i)a , p(j)b ;ψdk)
[p
(j)
b − C(p(i)a , p(j)b ;ψdk)][p(i)a − C(p(i)a , p(j)b ;ψdk)]
= ψdk , (5.5)
where the bivariate distribution C(p(i)a , p
(j)
b ;ψdk) with association parameter ψdk is
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given by,
C(p(i)a , p
(j)
b ;ψdk)
= Pr(Ta = 1, Tb = 1|dk)
=
[1 + (ψdk − 1)(p(i)a + p(j)b )]−
√
[1 + (ψdk − 1)(p(i)a + p(j)b )]2 − 4ψdk(ψdk − 1)p(i)a p(j)b
2(ψdk − 1)
.
5.2.1 Likelihood and Parameter Estimation
Variables Ta and Tb cannot be observed, and therefore, estimation of parameters
of models in equations (5.1) and (5.2) is not straightforward. The GCR-CRM for
combined drugs predicts the values for Ta and Tb using the EM algorithm (Dempster
et al., 1977). The observed outcomes n(k)00 and n
(k) − n(k)00 are used in the expectation
step of the EM algorithm. The marginal likelihoods are used to estimate the model
parameters in equations (5.1) and (5.2). The association parameter is estimated using
the full likelihood.
EM Algorithm
1. Initial Step
Initial values for each parameter are estimated from patients already entered
into the trial. For the first cohort of patients, parameter values estimated from
the prior data are the initial values. Section 5.2.3 below explains the prior data.
2. Expectation Step
n
(k)
10 , n
(k)
11 , n
(k)
01 ∼ Multinomial
(
n(k) − n(k)00 ;
p
(k)
10
1− p(k)00
,
p
(k)
11
1− p(k)00
,
p
(k)
01
1− p(k)00
)
;
where, pjajb = Pr(Ta = ja, Tb = jb), ja, jb = 0, 1. The expected cell counts
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are given by,
E
[
n
(k)
10 | n(k), n(k)00
]
=
[
n(k) − n(k)00
]
p
(k)
10
1− p(k)00
,
E
[
n
(k)
01 | n(k), n(k)00
]
=
[
n(k) − n(k)00
]
p
(k)
01
1− p(k)00
,
E
[
n
(k)
11 | n(k), n(k)00
]
=
[
n(k) − n(k)00
]
p
(k)
11
1− p(k)00
.
3. Maximisation Step
The parameters αa, βa, αb, and βb are estimated using the marginal likeli-
hoods given by,
l(αa, βa | n(i)1+, da1:I ) =
I∏
i=1
[
p(i)a
]n(i)1+ [1− p(i)a ]n(i)−n(i)1+
l(αb, βb | n(j)+1, db1:J ) =
J∏
j=1
[
p
(j)
b
]n(j)+1 [
1− p(j)b
]n(j)−n(j)+1
,
where ‘+’ denote summing over the subscript it replaces.
The cross-ratio ψdk is estimated using the full likelihood given by,
l(γab | n(k)jajb , d1:K) ∝
K∏
k=1
1∏
ja=0
1∏
jb=0
[p
(k)
jajb
]
n
(k)
jajb .
The expectation step and the maximisation steps are alternated until conver-
gence. The converged parameter values are used to enrol the next cohort of
patients.
5.2.2 Dose Selection Criterion
The monotonicity of the dose combinations is unknown and, hence, dose escalation
or de-escalation of one or more drugs is complex. Different dose combinations may
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have similar joint toxicity probabilities, which leads to a number of dose combinations
being closest to the target toxicity probability. The dose selection criterion discussed
below is reminiscent of the criterion explained by (Yin and Yuan, 2009a).
Suppose φt is the target toxicity probability and the dose combination (dai , dbj) is
administered to the current cohort of patients. A Binomial distribution describes the
number patients who experienced adverse events over all enrolled patients. Under the
law of large numbers Normal distribution can be used as an approximation to Bino-
mial. Therefore, the estimated joint toxicity probability pˆiij approximately follows the
Normal distribution given by,
sin−1
(√
pˆiij
)
∼ N (µpiij , σpiij) ,
where, µpiij = sin
−1 (√piij), σ2piij = (4mij)−1, and mij is the number of patients
treated at the dose combination (dai , dbj). The arcsine transformation is used to retain
the homogeneity of variance assumption.
LetA be the set that contains the dose combinations (dai , dbj); i = 1 . . . I, j . . . J,
selected for a trial. A condition set for dose escalation is given by,
Pr
(
N(µpiij , σpiij) < φt
)
> ce, (5.6)
where ce is the probability cut-off for dose escalation. If condition (5.6) is satisfied
then (dak , dbl) ∈ A will be selected for the following cohort of patients, only if,
pˆiij < pˆikl, and |pˆikl − φt| < |pˆimn − φt|, for all (dam , dbn) ∈ A \ (dak , dbl),
where pˆikl is the estimated toxicity probability of the dose combination (dak , dbl). That
is, the dose combination (dak , dbl) has estimated toxicity probability higher than the
current dose combination and closer to the target toxicity probability than all other
dose combinations, excluding the current dose combination.
A condition set for dose de-escalation is given by,
Pr
(
N(µpiij , σpiij) > φt
)
> cd, (5.7)
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where, cd is the probability cut-off for dose de-escalation. If condition (5.7) is satisfied
then (dak , dbl) ∈ A will be selected for the following cohort of patients, only if,
pˆikl < pˆiij, and |pˆikl − φt| < |pˆimn − φt|, for all (dam , dbn) ∈ A \ (dak , dbl),
where pˆikl is the estimated toxicity probability of the dose combination (dak , dbl). That
is, the dose combination (dak , dbl) has estimated toxicity probability lower than the
current dose combination and closer to the target toxicity probability than all other
dose combinations, excluding the current dose combination.
If neither conditions (5.6) nor (5.7) are satisfied then the following cohort of
patients will be treated at the current dose combination. That is, neither dose escalation
nor de-escalation will be performed. If the current dose combination is the highest
toxic combination of (daI , dbJ ) and condition (5.6) is satisfied then the following
cohort of patients will be treated at the same dose combination. If the current dose
combination is the lowest toxic combination of (da1 , db1) and condition (5.7) is satis-
fied then the trial will be stopped early for safety.
This design methodology requires clinicians to specify a target toxicity probability
φt, probability cut-offs for dose escalation ce, and de-escalation cd. Values for these
constraints may be specified based on the information collected from pre-clinical and
individual phase I trials.
5.2.3 A Simulation Study for Bin-GCR-CRM for CD
The simulation study discussed in this section explores the characteristics of the design
methodology. Suppose four dose levels of drugs A and B are selected for a two-drug
combination trial with 32 patients. Eight discrete dose levels of two drugs provide
sixteen dose combinations. Dose levels of drug A and drug B used in this simulation
study are given by,
Drug A 300 mg 550 mg 800 mg 900 mg
Drug B 400 mg 500 mg 850 mg 950 mg
.
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Note that the design methodology uses actual doses, but they carry no biological
meaning in the dose estimation process. The dose levels specified for this simulation
study are non-linear and fictitious but reasonable. In an actual drug combination trial,
the smallest dose, dose increments, and the largest dose of each drug are decided from
the information of previously conducted clinical or non-clinical trials of the individual
drugs. The dose combinations used in this simulation study shows no pre-determined
pattern. Pre-determined pattern means, for instance, dose levels of drug B are two
times higher than the corresponding dose levels of drug A.
The target toxicity probability φt is set to 0.30. At the end of each trial, dose
combinations that have joint estimated toxicity probabilities within the range of [0.25,
0.32] are selected as successive MTD combinations. These successive MTD com-
binations are in the range of 2% higher and 5% lower toxic than the target toxicity
probability. To emphasise safety just 2% over the target toxicity probability is consid-
ered. To accommodate low toxic combinations which may be highly efficacious, the
lower bound of the toxicity is set to be 5%. In an actual drug development process,
these successive MTD combinations will be further tested for efficacy in a multi-arm
clinical trial setting.
This design methodology estimates a starting dose combination based on prior
information. Generally, drug combination trials are conducted after thorough inves-
tigation of the toxicity profile of each IND individually. The toxicity information
on individual drugs can be used to construct prior data. The Bin-GCR-CRM for
combined drugs requires toxicity outcomes of a low and a high dose level of each
individual drug. This prior data is used to estimate a starting dose. Furthermore, it
retains the sequential nature of the trial whenever toxicity outcomes are unobserved at
some dose combinations.
Suppose a low dose level of drug A, 250 mg, is 5% toxic and a high dose level,
2500 mg, is 98% toxic. Similarly, low and high dose levels of drug B, 200 mg and
2000 mg, are 5% and 85% toxic, respectively. These two individual dose levels of
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drugs A and B form four dose combinations. Figure 5.2 shows the prior dose combina-
tions and the toxicity probabilities each dose combination is believed to produce when
administered individually. For simplicity the joint toxicity probabilities are obtained
by multiplying the marginal toxicities at each dose combination. These probabilities,
at each dose combination, are used to estimate the association parameter ψdk . In an
actual trial, clinicians’ belief can be assigned as prior information for ψdk .
Figure 5.2: Prior data for Bin-GCR-CRM for combined drugs
Parameters of models in equations (5.1), (5.2), and (5.3) are estimated using the
prior data in Figure 5.2. A dose combination of (800 mg, 500 mg) has estimated joint
toxicity probability, 1 - Pr(Ta = 0, Tb = 0), closest to the target toxicity probability.
This dose combination is the starting dose for every trial simulated in this section.
The probability cut-off for dose escalation, ce is set to 0.35. That is, in population,
there is a 35% chance that a dose combination could have toxicity probability less
than the target toxicity probability. Similarly, the probability cut-off for dose de-
escalation, cd is set to 0.70. That is, in the population the chance of a dose combination
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having toxicity probability greater than the target toxicity probability is 70%. The
events, dose escalation and de-escalation, are mutually exclusive, and therefore, the
summation of ce and cd must be greater than one to have a unique decision
5.2.3.1 Scenarios to Analyse the Operating Characteristics of the Bin-GCR-CRM
for CD
Four scenarios are set to analyse the operating characteristics of the Bin-GCR-CRM
for CD design methodology. These scenarios represent the true toxicity probabilities
of each dose combination. The observed outcomes shown in Figure 5.1 (a) are sim-
ulated using the true toxicity probabilities of each scenario. The latent outcomes in
Figure 5.1 (b) are estimated using the expected counts obtained by the EM algorithm.
Ten thousand trials are simulated under each scenario. Each trial starts with the
starting dose combination, 800 mg of drug A and 500 mg of drug B. Every trial uses
the prior data shown in Figure 5.2. The information prior data carry is down weighted
as the trial progresses (Section 2.7.2).
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Table 5.1 shows the true toxicity probabilities and the selection percentage of each
dose combination under four different scenarios. Scenario 1 describes a situation
in which there are five targeted MTD combinations. Two (drug A, drug B) MTD
combinations, (300 mg, 950 mg) and (550 mg, 850 mg), have the actual toxicity
probability just below the target toxicity probability of 0.30. Another two MTD
combinations, (550 mg, 950 mg) and (800 mg, 500 mg) are set with the actual toxicity
probability just above 0.30. A dose combination of (800 mg, 400 mg) is set with the
true toxicity probability equal to the target toxicity probability. In this scenario, the
largest dose level of drug A, (900 mg) combined with every dose level of drug B is
highly toxic.
In scenario 1, over 53% of simulated trials selected the targeted MTD combina-
tions. Over six percent of trials selected the higher toxic dose combinations of (800
mg, 850 mg), (800 mg, 950 mg), (900 mg, 400 mg), (900 mg, 500 mg), (900 mg,
850 mg), and (900 mg, 950 mg) as the MTD. Low toxic dose combinations of (300
mg, 400 mg), (300 mg, 500 mg), (300 mg, 850 mg), (550 mg, 400 mg), and (550 mg,
500 mg) are selected as the MTD by 17.24% of trials. Over 23% of simulated trials
stopped early due to the safety stopping rule set in Section 5.2.2.
Scenario 2 sets the true toxicity probability of the drug combinations within the
lower limit of 0.04 and the upper limit of 0.42. In this scenario, the lower dose
combinations are defined to have very low toxicity probability. The first two dose
levels of drug A, 300 mg and 550 mg, produce a low joint toxicity effect when
combined with every dose level of drug B. The targeted MTD combinations are (800
mg, 400 mg), (800 mg, 500 mg), and (800 mg, 850 mg). The highest dose level of drug
A produces higher toxicity probability when combined with every dose level of drug
B. Over 49% of simulated trials correctly selected the targeted MTD combination.
Over 16% of trials selected the higher toxic dose combinations. Note, the higher toxic
dose combinations of (800 mg, 950 mg), (900 mg, 400 mg), and (900 mg, 500 mg)
have their true toxicity probability much closer to the target toxicity probability. Under
this scenario, about 3.5% of simulated trials stopped early.
In scenario 3, every dose level of drug A combined with the highest dose level,
950 mg, of drug B are the targeted MTD combinations. In addition, this scenario
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targets the dose combination (900 mg, 850 mg). In contrast to scenarios 1 and 2, in
this scenario, the first two dose levels of drug B have a low toxicity probability when
combined with drug A dose levels. The highest toxic dose combination, (900 mg,
950 mg), of this scenario is one of the targeted MTD combinations. Over 56% of the
trials successfully selected the targeted MTD combinations. Under this scenario, a
large proportion of trials (39.08%) selected the lower toxic dose combinations. This
scenario shows that when the MTD combinations are at the right edge of the dose
space, some trials tend to select the adjacent lower toxic dose combinations.
The majority of scenario 4 dose combinations are highly toxic. This scenario
targets three dose combinations, (800 mg, 400 mg), (800 mg, 500 mg), and (900 mg,
400 mg). Only four dose combinations, (300 mg, 400 mg), (300 mg, 500 mg), (550
mg, 400 mg), and (550 mg, 500 mg), of this scenario have low toxicity probability.
Over 37% of the simulated trials selected the targeted MTD combinations. About 36%
of the trails stopped early. This is because eight dose combinations of this scenario
are extremely toxic and, therefore, most trials are pushed towards the lowest dose
combination. If the estimated toxicity probability of the lowest dose combination of
a trial is high then the trial stops early. Scenario 4 shows that if the true toxicity
probability of some dose combinations in the dose space are highly toxic, more trials
will stop early.
This simulation study shows that the binary version of the global cross-ratio con-
tinual reassessment method for combined drugs design mostly selects the targeted
MTD combinations. The design methodology performs well under the four different
scenarios discussed in this section. However, this design methodology ignores the
severity of the adverse events. The severity of each adverse event provides addi-
tional information about the administered dose combination and, therefore, crucial
in estimating a dose combination. The next section of this chapter incorporates the
severity information of adverse events into the GCR-CRM for Combined Drugs design
methodology.
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5.3 Ordinal Global Cross-Ratio Continual Reassessment Method
for Combined Drugs
Severity of adverse events should be incorporated to more accurately capture the
interaction effect of combined drugs. This section incorporates the severity of the
toxicity outcome into the dose-finding design methodology for combined drugs. The
Bin-GCR-CRM for combined drugs is extended to accommodate an ordinal outcome.
Suppose toxicity is observed on a 1 to 3 ordered scale, with adverse event scores
of 1 to 3 being ‘mild’, ‘moderate’, and ‘severe or life-threatening’ adverse events,
respectively.
Figure 5.3: (a) observed outcomes and (b) unobserved
outcomes for Ord-GCR-CRM for combined drugs
Figure 5.3 (a) shows the observed toxicity outcome after administering a dose
combination of drug A and drug B. The source of the observed toxicity (drug A or
drug B) is unknown. Figure 5.3 (b) shows the latent toxicity outcomes and their
classification into observed outcomes. For each cell, the observed outcome is deter-
mined by the maximum latent toxicity grade. If mild toxicity is observed it is caused
from mild toxicity of both drugs. If moderate toxicity is observed it is caused by the
combination of, moderate toxicity of drug A and either mild or moderate toxicity of
drug B, or vice versa. If severe or life-threatening toxicity is observed then it is caused
by the combination of, severe or life-threatening toxicity of drug A and either mild,
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moderate or severe or life-threatening toxicity of drug B, or vice versa.
The cumulative logistic models in equations (5.8) and (5.9) capture the marginal
effects of each drug. The marginal dose-toxicity models are given by,
Pr(Ta ≥ ra|dai) =
exp(γara + δadai)
1 + exp(γara + δadai)
, ra = 2, 3. (5.8)
Pr(Tb ≥ rb|dbj) =
exp(γbrb + δbdbj)
1 + exp(γbrb + δbdbj)
, rb = 2, 3. (5.9)
The intercept represents the baseline marginal toxicity probability estimate when
the dose of drug A or drug B is zero respectively. Slope parameters δa and δb represent
the change in toxicity probability that would result from a unit change in dose of
drug A and drug B respectively. The global cross-ratio between latent ordinal toxicity
outcomes can be used to estimate the joint drug-drug effect.
The latent design grid in Figure 5.3 (b) dichotomised at (ra, rb) to a 2x2 contin-
gency table given by,
{Ta ≤ ra, Tb ≤ rb} {Ta ≤ ra, Tb > rb}
{Ta > ra, Tb ≤ rb} {Ta > ra, Tb > rb}
, (5.10)
where, ra, rb = 2, 3. The interaction between drug A and drug B is modelled using
the log cross-ratio, given by,
ψ(ra, rb, dk) = exp(ζab dk), (5.11)
where, dk = dai + dbj , k = 1, . . . , K ,K = I × J , and the global cross-ratio
ψ(ra, rb, dk) is given by,
ψ(ra, rb, dk) =
Pr(Ta ≤ ra, Tb ≤ rb|dk) Pr(Ta > ra, Tb > rb|dk)
Pr(Ta ≤ ra, Tb > rb|dk) Pr(Ta > ra, Tb ≤ rb|dk) . (5.12)
The latent design grid can be dichotomised in four different ways. For each
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dichotomisation, equation (5.4) holds with the association parameter ψdk replaced
by ψ(ra, rb, dk). Model (5.11) assumes that ψ(ra, rb, dk) does not depend on the
dichotomisation cut points (ra, rb).
5.3.1 Estimation of Model Parameters
The classification of an observed mild outcome into a latent ordinal outcome (Figure
5.3 (b)) assumes that the observed mild outcome is produced from mild toxicity caused
by both drugs. This observed mild toxicity data is used in estimating the model param-
eters. However, a moderate toxicity outcome may be caused by three different latent
grid cells. Similarly, the source of the observed severe or life-threatening toxicity
outcome may be caused by five different latent grid cells.
Let n(k)jajb be the latent cell toxicity counts and p
(k)
jajb
be the corresponding cell
probabilities for ja, jb = 1, . . . , 3. The distribution of latent moderate toxicity is given
by,
n
(k)
21 , n
(k)
22 , n
(k)
12 | n(k)m ∼ Multinomial
(
n(k)m ;
p
(k)
21
p
(k)
m
,
p
(k)
22
p
(k)
m
,
p
(k)
12
p
(k)
m
)
;
where, n(k)m is the number of observed moderate toxicities and p
(k)
m = p
(k)
21 +p
(k)
22 +p
(k)
12 .
The distribution of latent severe or life-threatening toxicity is given by,
n31, n32, n33, n23, n13 | ns ∼ Multinomial
(
ns;
p31
ps
,
p32
ps
,
p33
ps
,
p23
ps
,
p13
ps
)
;
where, ns is the number of observed severe or life-threatening toxicities and ps =
p31 + p32 + p33 + p23 + p13.
The expected moderate and severe cell toxicity counts are used in the EM al-
gorithm until convergence of model parameters (Section 5.2.1). Converged model
parameter values are used to estimate a dose combination for the following cohort of
patients.
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5.3.2 Dose Selection Criterion
Severe or life-threatening toxicity caused by one or both drugs is considered ‘dose-
limiting’. The Ord-GCR-CRM for combined drugs selects dose levels based on the
joint toxicity probability Pr(Ta ≥ 3, Tb ≥ 3). The dose selection criterion is iden-
tical to Bin-GCR-CRM for Combined Drugs discussed in Section 5.2.2, with pˆiij =
Pˆr(Tai ≥ 3, Tbj ≥ 3).
5.3.3 A Simulation Study for Ord-GCR-CRM for CD
This simulation study is set to explore the operating characteristics of the design
methodology. This simulation is set with a sample size of 32, a cohort size of 4,
and the dose levels described in Section 5.2. The target toxicity probability φt, the
probability cut-offs for dose escalation ce and de-escalation cd are set to 0.30, 0.35 and
0.70 respectively. The prior information required for Ord-GCR-CRM for combined
drugs is toxicity outcome of a low and a high dose level of each individual drug with
additional severity information.
Suppose a low dose level of drug A, 250 mg, yields 75% mild, 20% moderate, and
5% severe or life-threatening adverse events. A high dose level of drug A, 2500 mg,
yields 1% mild, 1% moderate, and 98% severe or life-threatening adverse events.
Similarly, a low dose level of drug B, 200 mg, yields 70% mild, 25% moderate, 5%
severe or life-threatening and a high dose level of drug B, 2000 mg, yields 5% mild,
10% moderate, and 85% severe or life-threatening adverse events.
For the first cohort of patients, parameters of models in equations (5.8), (5.9),
and (5.11) are estimated using this prior information. In this simulation study, for
simplicity, the marginal toxicity probabilities of the prior data are multiplied in order
to obtain the joint cell toxicity probabilities at each dose combination. The amount of
information prior data carries is diminished as a trial progresses. A dose combination
of (300 mg, 850 mg) has the estimated joint toxicity probability, Pr(Ta ≥ 3, Tb ≥ 3),
closest to the target toxicity probability. This dose combination is the starting dose for
every trial simulated in this section.
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5.3.3.1 Scenarios to Analyse the Operating Characteristics of the Ord-GCR-CRM
for Combined Drugs
Four scenarios are considered to analyse the operating characteristics of the design
methodology. These scenarios represent the true probabilities of mild, moderate and
severe or life-threatening adverse events. These true probabilities are used to simulate
the observed toxicity outcomes.
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Table 5.2 shows the true toxicity probabilities of mild, moderate, and severe or
life-threatening toxicities at each dose combination. Scenario 1 assumes the last two
dose levels of drug B, 850 mg and 950 mg, are toxic when combined with every dose
level of drug A. This scenario targets three dose combinations of (300 mg, 850 mg),
(550 mg, 850 mg), and (800 mg, 850 mg) as the MTD. The true toxicity probability of
severe or life-threatening adverse events of the highest dose level of 950 mg is greater
or equal to 0.40, when combined with every dose level of drug A. The true toxicity
probability of moderate adverse events of the lowest dose combination is 0.40. That is,
every other dose combination has more than a 40% chance of producing a moderate
toxicity. The highest toxic dose combinations of, (800 mg, 850 mg), (800 mg, 950
mg), (900 mg, 850 mg), and (900 mg, 950 mg) produce no mild toxicity outcomes.
Scenario 2 assumes that highest dose levels of drug A, 800 mg and 900 mg, are
toxic when combined with every dose level of drug B. Every dose level of drug B
is targeted as the MTD when combined with 800 mg of drug A. The true toxicity
probability for moderate adverse events of targeted MTD combinations are around
0.60. The lowest dose combination of (300 mg, 400 mg) is set with high probability
of mild toxicity and the highest dose combination of (900 mg, 950 mg) is set with
almost zero probability of mild toxicity.
Scenario 3 targets four dose combinations, (800 mg, 850 mg), (800 mg, 950 mg),
(900 mg, 400 mg), and (900 mg, 500 mg) as the MTD. In contrast to scenarios 1 and
2, the targeted dose combinations of this scenario vary between two high dose levels
of drug A and all dose levels of drug B. The true toxicity probability of severe or life-
threatening adverse events varies between 0.07 and 0.36. This means a few simulated
trials will stop early due to higher toxic adverse events.
Scenario 4 targets two dose combinations of (300 mg, 850 mg) and (550 mg, 850
mg). The adjacent dose combinations of these MTD combinations are set with very
high or low dose limiting toxicity probabilities. The range of severe or life-threatening
toxicity probability is between 0.02 and 0.77. Over 50% of dose combination are set
with high dose-limiting toxicities, and therefore, under this scenario most trials are
expected to stop early.
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Table 5.3 summarises the ten thousand simulated trial outputs. Under each sce-
nario, the first five columns represent the selection percentage of each dose combi-
nation, the sixth column corresponds to the selection sum percentage of the targeted
MTD combinations, the seventh column shows the percentage of inconclusive trials,
and the remaining columns shows the number of simulated mild, moderate and severe
or life-threatening outcomes averaged over ten thousand trials.
Selection sum percentage of MTD combinations is 52.34% at scenario 1. It slightly
increases to 54.23% at scenario 2, and then slightly drops to 43.33 in scenario 3,
where it dramatically decreases to 15.6% in scenario 4. Scenario 1 and 2 shows the
Ord-GCR-CRM for CD performs well whenever a few dose combinations have true
dose-limiting toxicities greater than the target toxicity probability. In scenario 3, more
trials select the adjacent low toxic dose combinations. In scenario 4, most completed
(15.6% of 22.7%) trials select the targeted MTD combinations.
Early stopping is just over 4% in scenario 1, where it increases to 15.69% in sce-
nario 2. The dose-limiting toxicity of the dose combinations in scenario 2 are slightly
higher than scenario 1, and therefore, more trials in scenario 2 tend to de-escalate to
the adjacent lower dose combination. If the estimated dose combination is the lowest
dose combination then the trial stops prematurely. In scenario 3, the percentage of
early trial stops is 13.47%, where it dramatically increases to 77.3% in scenario 4.
In scenario 4 only 25% (four out of sixteen) dose combinations has the dose-limiting
toxicity below the target toxicity probability. Most trials rapidly de-escalates to the
lowest dose combination and stops prematurely. The design methodology is risk
averse because of the huge number of trials stops early in scenario 4.
The number of mild toxicity events per trial is 2.47 in scenario 1, where it peaks
to 6.50 at scenario 2 and slightly drops to 6.38 in scenario 3. The highest number
of moderate toxicity events (21.31) is simulated per trial in scenario 1, because this
scenario is set with high true toxicity probabilities for moderate toxicity. Moderate
toxicity is simulated in scenario 2 is 14.57, where it slightly increases to 15.3 in
scenario 3. The number of dose-limiting toxicity (severe or life-threatening) events
per trial oscillates around 6, from scenarios 1 to 3. Scenario 4 was chosen to show
the safety of the design methodology. A large proportion of trials stopped early, and
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therefore, toxicity outcomes are not accountable.
5.4 Key Features of the Global Cross-Ratio Continual Reassess-
ment Method for Combined Drugs
The GCR-CRM for CD developed in this chapter has some distinctive attributes.
Dose levels of each drug are multiplied on the scale of cross-ratio in order to mea-
sure the joint toxicity effect. This assumes that both drugs produce similar toxicity
effects in combination. If the drugs are expected to behave relatively differently
in combination then equation (5.3) needs to be altered. For instance, if drug B is
expected to cause more toxicities than drug A then equation (5.3) is replaced by,
ψ(dai ,dbj ) = exp(γab(dai + ρdbj)). The parameter ρ (> 1) indicates that dose dbj
causes more toxicities than dai , when administered together. Several alterations can
be made to the design methodology, according to a specific requirement of the inves-
tigating new drug combinations. The GCR-CRM for CD is in its early stage of the
development. This chapter only discusses the basic form of the design methodology.
The dose level of each drug used in the design methodology is merely a num-
ber. These number values carry no biological information. The design methodology
is functional with any dose level. However, the dose values may cause numerical
outflows, if they are not of similar sizes. For example, dose units of drug A are
in thousands, where as drug B is in decimals. Computational nuisances must be
prevented by scaling the dose levels to numerically well behaved values. An option is
to standardise dose levels of both drugs to fit between zero and one. This will lead to
a standardised or scaled MTD estimate.
This chapter describes the methodology for two drug combinations. However, the
methodology can be simply extended to accommodate more than two drugs. Consider
a drug combination trial with three drugs. Each drug will have marginal dose toxicity
relationship modelled using logistic models, identical to models in equations (5.8) and
(5.9). The interaction effect between three drugs can be modelled using three dimen-
sional cross-ratios. Molenberghs and Lesaffre (1994) describe the theoretical basis for
multi-dimensional cross-ratio modelling using the multivariate Plackett distribution.
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The decision on dose escalation, de-escalation or staying at the same dose is adap-
tively based on the sequentially accruing toxicity data. The distribution of estimated
toxicity probability in the population, N
(
µpiij , σpiij
)
, is used in deciding the dose
selection. Cohorts of patients are sequentially entered to the trial. The proportion
of observed toxicities is small after each sequence. The estimation of population
variance, σ2piij , heavily depends on this small value. The homogeneity of variance
assumption is retained using the arcsine transformation. This transformation equalises
the population variance based on the number of patients entered into the trial.
The observed outcome in the ordinal version of the GCR-CRM for CD is deter-
mined by the maximum latent toxicity (Figure 5.3). Such a strong assumption prevents
the comparison of Ord-GCR-CRM for CD with Bin-GCR-CRM for CD. However, this
assumption is crucial. It assumes the toxicity effect of both drugs is identical. This
assumption is similar to the assumption made in equation (5.11). This assumption can
be altered based on the expected behaviour of drugs. Suppose the interaction effect
is mostly caused by drug B rather than drug A then the assumption can be altered as
shown in Figure 5.4.
Figure 5.4: (a) observed outcomes, (b) values allocated for cells
and (c) latent outcome for Ord-GCR-CRM for CD, if Drug B is
expected to cause more toxicity than drug A
Figure 5.4 will replace Figure 5.3, if drug B is believed to cause more toxicity
than drug A. Part (b) of the figure shows that the latent ordinal outcome of drug B is
multiplied by two and the maximum of drug B and drug A ordinal outcomes is given
to the relevant grid cell. The observed outcome, part (a) of the figure, is lined with
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part (c) of the figure. A grid cell value of two is linked to the observed mild toxicity. A
grid cell value of three or four is linked to the observed moderate toxicity and a value
of six is linked to severe or life-threatening toxicity. This assumption considerably
relies on clinicians’ belief about the drug-drug interaction. A wrong belief will lead
to a wrong decision on MTD estimation.
In conclusion, this chapter presents a newly developed drug combination design
methodology. This methodology uses the global cross-ratio model. The dose selection
is made using the joint toxicity probability while preserving the marginal toxicity
effect of each drug. The toxicity surface of the dose combinations is re-estimated
during every sequence of the trial using the model parameters. A binary and an ordinal
version of the design methodology are described in this chapter. Two simulations
studies shows GCR-CRM for combined drugs have a fair operating characteristic in
selecting the appropriate MTD combinations. The design methodology can be further
modified to accommodate different clinicians’ belief.
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Chapter 6
Conclusions and Recommendations
6.1 Discussion
The CRM, first proposed by O’Quigley et al. (1990), has received great attention
over the past two decades. The original CRM uses a single parameter model under a
Bayesian paradigm. It requires clinicians to specify a toxicity probability at each dose
level. In addition, it requires a prior distribution for the single model parameter. This
makes the original CRM design methodology sophisticated for clinicians and difficult
to use in practice. The prior distribution used in the original CRM is uninformative.
That is, it does not reflect the available prior data. Eliciting a prior distribution from
the data requires enormous work. Furthermore, the influence of the prior distribution
is not diminished as a trial progresses. For these reasons, this thesis focuses on a
pragmatic CRM rather than a fully Bayesian CRM.
The practicality of the CRM is generally not discussed in statistical and medi-
cal literature (Dent and Eisenhauer, 1996). This also slows down the uptake of the
methodology in practice. Jaki (2013) found that about two-thirds of the clinical
trials units in the United Kingdom are aware of the CRM but all dose-finding trials
were designed using conventional dose-finding design methodologies. Approximately
seven years ago, Rogatko et al. (2007) claimed a similar argument: among the trials
recorded in the Science Citation Index database between 1991 and 2006, only a few
phase I cancer trials were designed using sound statistical procedures.
Clinicians prefer conventional dose-finding designs because they have been around
117
118 CHAPTER 6. CONCLUSIONS AND RECOMMENDATIONS
and in use for a long period, they are simple to understand, and it is quick to set up
a trial (Christophe Le Tourneau, 2009, Iasonosa and O’Quigley, 2011). However,
conventional dose-finding designs have been proven to be inaccurate in dose level
estimation (Reiner et al., 1999). These designs are memoryless, meaning a dose level
is selected based on observations from the most recent patients information and all
other toxic effects are ignored (O’Quigley and Zohar, 2006). Iasonos et al. (2008)
prove that the CRM more accurately estimates the true MTD and treats more patients
at the optimum dose level, compared to conventional design methodology. Using
conventional dose-finding design methodologies for the reason of simplicity is illog-
ical and scientifically invalid. Jaki et al. (2013) support this argument, conventional
dose-finding design methodologies are not recommended for statistical and practical
reasons.
Some CRM type designs, which are extraneous to the objectives of this thesis,
may be preferred by some clinicians. Pan et al. (2013) argue that clinicians in China
prefer dose-finding design methodology based on modified toxicity probability inter-
vals (Ji et al., 2010) over the CRM. Dose-finding designs based on toxicity probability
intervals, first proposed by Ji et al. (2007), select a dose with actual toxicity within the
window of target φ. Designs discussed in this thesis can be extended to have target
intervals: (0, φ− 1), [φ− 1, φ+ 2], and (φ+ 2, 1) for the toxicity probability. The
upper limit, 2 is equivalent to the safety constraint discussed in this thesis. A value
for 1 and updated toxicity intervals (credible interval in Bayesian Statistics) at each
dose level need to be determined. Designs developed in this thesis are in their early
from. At this stage, we have decided to leave the design methodologies in the present
form.
Escalation with overdose control (EWOC) may attract some clinicians (Babb et al.,
1998) over the CRM. This design methodology controls the overdose probability
(probability of the estimated dose exceeding the MTD) using an asymmetric function
that penalises doses above the target. This methodology may treat fewer patients
at doses above the targeted dose, compared to the CRM. However, it focusses on
overdose control rather than accuracy of the optimum dose level. Chu et al. (2009)
compared the CRM with EWOC and found that the CRM has a better convergence
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rate compared to EWOC, but that EWOC provides better overdose protection than
the CRM. This thesis concentrates on estimating an accurate optimum dose and thus
ignores the EWOC concept. The CRM overpowers other dose-finding design method-
ologies that are based on sound statistical procedures.
Tradition is the only justification for clinicians to keep using conventional design
methodologies and ignoring the CRM. Statistical reasoning, clinical evidence and
conceptual thinking are disregarded in practice. Clinicians are slowly getting out of
their comfort level and starting to use design methodologies based on sound statistical
procedures. Ivanova et al. (2013) argue that the CRM and its modifications are making
their way into dose-finding trials run by the pharmaceutical industry. The pragmatic
approach taken in this thesis would definitely bring forth clinicians to design dose-
finding trials using the CRM. An increased use of the CRM can be anticipated in the
future.
6.2 Summary of the Research
This thesis presents three novel dose-finding design methodologies. The first
design methodology incorporates adverse event relatedness into dose-finding design
methodology based on toxicity only. The second is a bivariate dose-finding design
methodology which accounts for late-onset efficacy outcomes and effectively esti-
mates the optimum biological dose (OBD) using an interaction effect between toxicity
and efficacy. The last design methodology estimates the joint toxicity interaction of
two drugs using latent contingency tables. A simple binary version and a detailed
ordinal version of all three design methodologies are presented.
All methodologies extend the pragmatic version of the CRM proposed by Pianta-
dosi et al. (1998). These novel design methodologies use logistic models with more
than one parameter. The use of logistic models is reasonable because the mathematical
structure of the logistic model represents the biological dose-response form. The
model parameters are estimated by using the mixture of actual data and prior data.
The initial values for the model parameters are estimated using clinicians’ judgement
formalised as ‘prior data’. This information is combined with the sequentially accu-
mulating actual data. The relative weight given to the prior data is diminished once
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the actual data starts accumulating. All the design methodologies developed in this
thesis are efficient, flexible and practical.
Chapter 3 introduced a new dose-finding design methodology, the Aerd-CRM,
which considered the uncertainty of an adverse event. That is, whether an adverse
event observed during the trial is related to the IND. The relatedness of an adverse
event was categorised into two. Toxicity probabilities were estimated based on these
two adverse event categories. The maximum of the estimated toxicity probabilities
was used to select dose levels. Simulation studies described in this chapter provided
convincing evidence that dose-finding design methodologies should incorporate ad-
verse event relatedness. Incorporating adverse event relatedness into the CRM brings
a new dimension to this design methodology.
The bivariate dose-finding design methodology, GCR-CRM presented in Chapter
5 has a flexible parametric structure that accounts for marginal dose-toxicity, dose-
efficacy relationships, and the toxicity-efficacy interaction. The dose-efficacy relation-
ship is assumed to be either monotone increasing or uni-modal or monotone decrease.
The design used a parsimonious model for this relationship which contains the highest
efficacious dose as a parameter to be estimated. Furthermore, the GCR-CRM took
into account late onset efficacy outcomes using the EM algorithm. This shows that the
GCR-CRM is realistic in handling efficacy data. A unique feature of the GCR-CRM
is the use of the global cross-ratio for the complex toxicity-efficacy interaction. The
estimated interaction effect at each dose level was indirectly used for the dose selection
criterion. The dose level which has the highest joint toxicity efficacy probability
Pr(E = 1, T = 0), and marginal toxicity probability closest to the toxicity cut-off
is selected as the OBD. An ordinal version of the GCR-CRM described in Chapter
4 improves the dose estimation process by using additional severity of toxicity and
disease progress rate of efficacy information. Two simulation studies described in this
chapter show that the GCR-CRM has satisfactory operating characteristics.
Chapter 4 extended the concept of GCR-CRM for phase I drug combination trials
to the so called GCR-CRM for combined drugs (CD). The initial form of this novel
methodology, phase I drug combination trials with two drugs, was described in this
chapter. A distinctive feature of the GCR-CRM for CD is its additive use of each dose
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level of each drug on an exponential scale. Therefore, the joint toxicity is measured
by assuming both drugs produce similar toxicity effects in combination. The joint
toxicity probability of each dose combination was estimated during each sequence
of the trial. The dose selection was made using the joint toxicity probability while
preserving the marginal toxicity effect of each drug. A binary and an ordinal version
of the design methodology were described in this chapter. Two simulations studies
show that the GCR-CRM for the combined drugs has fair operating characteristic in
selecting the appropriate MTD combinations.
Simulation studies discussed in this thesis use reasonable values for the clinical
parameters. For example, the conventional value for the target toxicity probability of
a phase I dose-finding design varies between 20% and 30% (Cheung, 2011). Chap-
ter 3 uses 25% as the target toxicity probability. The use of 25% is reasonable, a
target value outside the range (20%, 30%) should be justified by clinicians. In the
simulation studies, values used for the clinical parameters (e.g., number of test dose
levels, number of patients) are within the range of the values used in standard clinical
practice.
A few convincing scenarios are shown under each simulation study. These scenar-
ios represents true toxicity or efficacy probabilities. They were created using a trial
and error approach. That is, numerical values were give to the model parameters and
the dose-toxicity or dose-efficacy curves were plotted. Then a few trials were simu-
lated and the nature of the scenario was observed. Several scenarios were examined
and a few compelling scenarios were chosen and are discussed in the thesis. A vast
number of scenarios could be created under each simulations study, but the scenarios
discussed in the thesis are ones worth exploring.
6.3 Recommendations
The three novel dose-finding design methodologies presented in this thesis can
be modified to be suitable for different clinical circumstances. A modification or
extension made to these design methodologies should not purely be a research exercise
in design methodology but should rather be a pragmatic design concept. Any exten-
sion should carefully consider the limitations of these design methodologies. This
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section suggests some possible extensions and limitations of the design methodologies
presented in this thesis.
The Aerd-CRM presented in Chapter 3 has the key characteristics of CRM with
additional information on ordinal toxicity outcome and adverse event relatedness. In-
corporating adverse event relatedness into CRM opens up further investigation into the
CRM design methodology. Combining the Aerd-CRM concepts with the TITE-CRM
discussed in Section 2.4 would further improve the CRM with late-onset toxicities.
However, the Aerd-CRM demands clinicians to accurately classify the drug related
adverse events into two categories ‘doubtful or possible’, and ‘probable or definite’.
A wrong classification can lead to an inaccurate MTD estimation.
The GCR-CRM presented in Chapter 4 uses flexible parametric models to estimate
an OBD. The Aerd-CRM concept in Chapter 3 can be combined with GCR-CRM.
Such an extension would require efficacy relatedness to the IND. Another possible
extension of the GCR-CRM would incorporate late-onset toxicity outcomes. Cur-
rently, the GCR-CRM only considers late-onset efficacy outcomes. The TITE-CRM
in Section 2.4 can be used to incorporate late onset toxicity outcomes.
The GCR-CRM for CD described in Chapter 5 only considers two drug combi-
nations. This methodology can be simply extended to accommodate more than two
drugs using a multivariate Plackett distribution. Furthermore, incorporation of adverse
event relatedness (the Aerd-CRM concept) into the GCR-CRM for CD would yield
reliable MTD combination. A limitation of the GCR-CRM for CD is the assumption
that the toxicity effect of both drugs are identical. Such a conservative assumption can
be altered based on the expected behaviour of drugs. All three design methodologies
presented in thesis enhance the CRM.
Appendix A
A Simulation Study of Software Programs
Discussed in Chapter 2
This simulation study is set with the target toxicity probability φt = 0.20, sample size
N = 24, and number of test dose levels K = 6. In addition, the cohort size is set
to three. For safety reasons, trials begin with the lowest dose level and never escalate
by more than one dose level above the patients’ previous dose. The trial will stop
whenever 24 (sample size) patients are treated.
Table A.1: Dose levels and prior p(tox) values
Dose No. Dose description Prior p(tox)
1 0.6 mg/kg 0.05
2 0.8 mg/kg 0.1
3 1.2 mg/kg 0.2
4 1.8 mg/kg 0.35
5 2.7 mg/kg 0.5
6 3.6 mg/kg 0.7
Table A.1 displays the dose levels, but it is the prior probability of toxicity (prior
p(tox)), known as the skeleton in CRM, which plays the key role in differentiating
dose levels. The prior probabilities here are based on the work of Goodman et al.
(1995). To ensure the dose levels are assigned a reasonable range of prior probability
of toxicities, the prior probability of the lowest dose levels is set to less than the target
probability of toxicity and the highest dose level is set with greater than the φt.
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Table A.2: True p(tox) values for each scenario
Dose No. Dose Scene 1 Scene 2 Scene 3 Scene 4 Scene 5 Scene 6
1 0.6mg/kg 0.20 0.11 0.05 0.02 0.01 0.01
2 0.8mg/kg 0.35 0.20 0.1 0.05 0.03 0.01
3 1.2mg/kg 0.54 0.36 0.2 0.10 0.06 0.03
4 1.8mg/kg 0.72 0.55 0.35 0.20 0.12 0.05
5 2.7mg/kg 0.83 0.69 0.5 0.32 0.20 0.10
6 3.6mg/kg 0.92 0.84 0.7 0.52 0.37 0.20
Table A.2 shows the six scenarios set for simulation, each of which is repeated
10,000 times. Different sets of probabilities are given for the dose levels in each
scenario. These sets of probabilities represent the ‘true probability of toxicity’ for
the purpose of simulation. The first scenario has a starting dose with the highest
probability of toxicity. The third scenario is set up so that the true probability of
toxicity is equal to the prior probability.
Table A.3: Scenario and the target dose level
Scenario Multiplier Targeting dose
Scenario 1 4.75 Dose level 1 (0.6mg/kg)
Scenario 2 2.25 Dose level 2 (0.8mg/kg)
Scenario 3 1.00 Dose level 3 (1.2mg/kg)
Scenario 4 0.46 Dose level 4 (1.8mg/kg)
Scenario 5 0.25 Dose level 5 (2.7mg/kg)
Scenario 6 0.11 Dose level 6 (3.6mg/kg)
Table A.3 illustrates the multiplier used to calculate the true probability of toxic-
ities. The odds of the prior probability of toxicity for each dose are calculated (odds
= probability/(1-probability)). The true probability of toxicity for the dose i of the
scenario i (i = 1 . . . 6) is fixed with the target probability of toxicity. The odds of
the target probability of toxicity is 0.25 (0.2/0.8). A multiplier for each scenario is
calculated by dividing 0.25 by the corresponding prior odds (multiplier of the scenario
i = 0.25/prior odds of dose i; i = 1 . . . 6). Odds for the other dose levels of each
scenario are calculated by multiplying the prior odds by the corresponding multiplier.
The odds are converted back to probability (probability = odds/(1+odds)).
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This simulation is conducted in each software program reviewed in Chapter 2.
Section A.1 runs the simulation using the R package ‘dfcrm Version 0.2-2’. Section
A.2 uses the ‘bCRM Version 1.1.3’ which is designed to implement the bivariate CRM
discussed in Section 2.5. Section A.3 illustrate the software program ‘CRM Version
1.0’ which contains an additional feature to simulate ‘3+3’ designs.
A.1 Simulation using dfcrm version 0.2-2
The power model in equation (2.3) is selected, but it is the weighted likelihood in
equation (2.16) that plays the key role in TITE-CRM. A normal prior distribution with
mean 0 and variance 1.34 is assumed for β. The doses described in Table A.1 are used
for the design. Each scenario in Table A.2 is repeated 10,000 times separately with
the same seed for random number generation.
The ‘titesim’ function in dfcrm version 0.2-2 simulates a TITE-CRM trial. Patient
follow-up time is set to 6 time units (e.g., 6 months). TITE-CRM accrues patients
whenever they become available. A Poisson process with rate 3 is assumed for patient
arrival. That is, on average 3 patients arrive in every 6 (patient follow-up time) time
units. To simulate time-to-toxicity outcome uniform distribution in the interval [0, 6]
was assumed. Instead of uniform distribution, an Exponential or Weibull distribution
can be used. By default, the ‘titesim’ function assigns the linear weight in equation
(2.17).
Table A.4 shows the simulation results of six scenarios in the software program
dfcrm version 0.2-2. Scenario i is set to target dose level i as the MTD (i = 1 . . . 6).
The probability of selecting the targeted dose is 80% in scenario 1, it suddenly drops in
scenario 2 where it fluctuates around 50%. Number of patients treated at the targeted
dose is 16 in scenario 1, it decreases to half in scenario 2 where it remains constant.
A.2 Simulation using bCRM version 1.1.3
When the efficacy option in the bCRM software program is turned off the outcome
can be compared with the simulations in other software programs. Table A.1 describes
the doses and the skeleton. Figure A.1 shows the plot of the skeleton in the bCRM
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software program. The doses on the x-axis are calculated via the CRM backward
transformation in equation (2.2). The graph shows the dose-toxicity relationship for
different values of β with α0 = 3, and the skeleton is plotted for β = 1.0 (equation
2.4).
Figure A.1: A plot of the skeleton
This software program implements the ad hoc stopping rule first proposed by
Goodman et al. (1995). The trial stops whenever 18 (six cohorts) patients are enrolled
to the trial and 9 (three cohorts) patients are treated at a recommended dose level. This
ad hoc stopping rule does not harm the CRM protocol.
Figure A.2 shows toxicity results of each scenario after 10,000 simulations. The
dose strength on the x-axis are the actual dose levels. Broken lines (Est. ToxBound)
show 95% credible interval of the average posterior probability of toxicity. In scenario
1, the true probability of toxicity and the observed probability of toxicity of dose level
4 (1.8 mg/kg) are the same. The true p(tox) of dose levels 5 and 6 (2.7 mg/kg and 3.6
mg/kg) are out side the 95% credible interval of the estimated probability. The true
p(tox) of scenario 3 is set to match with the skeleton, but the observed probability of
toxicity of the first three dose levels are slightly lower than the true p(tox). The 95%
credible intervals for scenarios 4, 5 and 6 are narrow at lower dose levels and steadily
getting wider at high toxic dose levels.
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A.3 Simulation using CRM version 1.0
This section shows the simulation study in the CRM versiom 1.0 software pro-
gram. Implementation of add hoc stopping rules provided in the software program
means the trial will stop whenever 18 (six cohorts) patients are enrolled to the trial
and 9 (three cohorts) patients are treated at a recommended dose level. This simulation
uses the one-parameter logistic model with exponential prior distribution.
Table A.5 shows the probability of declaring MTD for each scenario. In scenario
1, dose level 1 (0.6 mg/kg) is targeted as the MTD (true p(tox) = 0.2). There is a
82% chance that the CRM will declare the dose level 1 as the MTD (p(CRM declares
MTD) = 0.8172). The observed CRM probability of toxicity for dose level 1 is closer
to the target probability of toxicity (Obs. CRM p(tox) = 0.1992 ≈ 0.2). In scenario 1,
the CRM selects dose level 1 as the MTD. It treats 13 patients at the MTD, whereas
the 3+3 design treats 5 patients at the dose level 1. In the 3+3 design, there is a 44%
chance that the MTD is dose level 1. There is a 33% chance that the 3+3 design
declares that the MTD is lower than dose level 1.
In scenario 6, the true probability of toxicity for dose level 6 is set to 0.2. However,
there is a high possibility the CRM selects dose level 5 as the MTD. This is due to the
high prior probability of toxicity for dose level 6 (0.7). Therefore, the CRM tends
not to choose a high toxic dose as MTD. There is a high possibility the 3+3 design
declares that the MTD is higher than dose level 6 (3+3: MTD is higher than dose level
6 ≈ 60%). It should be noted that the CRM declares a dose as MTD which has the
observed probability of toxicity closer to the target probability of toxicity. In each
scenario, the CRM treats slightly more patients at the MTD than the 3+3 design.
A.4 Comparison of the Software Programs Reviewed
Table A.6 compares software programs based on features, CRM method, model
implemented, stopping rule and output. All three software programs are available via
web sites, which are capable of conducting simulation and a single trial of original
CRM. Both dfcrm version 0.2-2 and CRM version 1.0 are not menu driven packages,
and provide both power and logistic CRM models. bCRM version 1.1.3 is specially
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designed to conduct bivariate CRM. It has excellent graphical output features, but its
scenario output does not provide the probability dose levels being selected as MTD
and the single trial output does not show the estimated posterior probability of dose
levels. The ad hoc stopping rule based on the work of Goodman et al. (1995) is
implemented in both bCRM version 1.1.3 and CRM version 1.0.
In conclustion, the simulation study shows the speciality of each software program
in conducting CRM modifications. The dfcrm version 0.2-2 implements both CRM
models and may be preferred by statisticians who are familiar with CRM and its
variations. However, it does not implement the bivariate CRM. Bivariate CRM has
several limitations and therefore this simulation study is set to examine the toxicity
outcome only. CRM version 1.0 is not user-friendly and should not be a choice unless
the operating characteristics of CRM has to be compared with ‘3+3’ design.
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Table A.4: dfcrm - Probability dose levels being MTD
Scenario Dose No. Dose p(tox) Select prob. No. Pat No. Tox
1 1 0.6mg/kg 0.200 0.802 15.853 3.167
2 0.8mg/kg 0.350 0.189 5.082 1.788
3 1.2mg/kg 0.540 0.009 1.943 1.060
4 1.8mg/kg 0.720 0.000 0.910 0.654
5 2.7mg/kg 0.830 0.000 0.210 0.172
6 3.6mg/kg 0.920 0.000 0.001 0.001
2 1 0.6mg/kg 0.110 0.282 8.155 0.896
2 0.8mg/kg 0.200 0.531 8.326 1.666
3 1.2mg/kg 0.360 0.183 5.206 1.875
4 1.8mg/kg 0.550 0.004 1.726 0.957
5 2.7mg/kg 0.690 0.000 0.569 0.393
6 3.6mg/kg 0.840 0.000 0.018 0.015
3 1 0.6mg/kg 0.050 0.021 2.944 0.149
2 0.8mg/kg 0.100 0.227 5.427 0.540
3 1.2mg/kg 0.200 0.563 8.903 1.773
4 1.8mg/kg 0.350 0.180 4.909 1.734
5 2.7mg/kg 0.500 0.008 1.656 0.838
6 3.6mg/kg 0.700 0.000 0.161 0.113
4 1 0.6mg/kg 0.020 0.001 1.531 0.031
2 0.8mg/kg 0.050 0.025 2.384 0.122
3 1.2mg/kg 0.100 0.255 6.123 0.613
4 1.8mg/kg 0.200 0.513 8.172 1.626
5 2.7mg/kg 0.320 0.200 4.958 1.586
6 3.6mg/kg 0.520 0.006 0.832 0.441
5 1 0.6mg/kg 0.010 0.000 1.252 0.012
2 0.8mg/kg 0.030 0.004 1.587 0.053
3 1.2mg/kg 0.060 0.066 3.548 0.212
4 1.8mg/kg 0.120 0.330 6.856 0.819
5 2.7mg/kg 0.200 0.501 8.061 1.616
6 3.6mg/kg 0.370 0.099 2.697 0.983
6 1 0.6mg/kg 0.010 0.000 1.115 0.011
2 0.8mg/kg 0.010 0.000 1.214 0.014
3 1.2mg/kg 0.030 0.011 1.999 0.061
4 1.8mg/kg 0.050 0.070 3.912 0.197
5 2.7mg/kg 0.100 0.398 8.192 0.801
6 3.6mg/kg 0.200 0.520 7.568 1.529
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Figure A.2: Scenario Toxicity Results
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Table A.5: CRM Version 1.0 Probability of declaring MTD
Dose No. Dose prior p(tox) true p(tox) p(CRM MTD) p(3+3 MTD) No. CRM pat No. 3+3 pat Obs. CRM p(tox)
Scenario 1
3+3: MTD is lower than dose 1 0.3272
1 0.6mg/kg 0.0500 0.2000 0.8172 0.4359 13.11 5.19 0.1992
2 0.8mg/kg 0.1000 0.3500 0.1711 0.2146 4.41 3.61 0.3431
3 1.2mg/kg 0.2000 0.5400 0.0116 0.0219 1.08 1.24 0.5407
4 1.8mg/kg 0.3500 0.7200 0.0001 0.0001 0.08 0.14 0.7163
5 2.7mg/kg 0.5000 0.8300 0.0000 0.0000 0.00 0.00 0.8333
6 3.6mg/kg 0.7000 0.9200 0.0000 0.0000 0.00 0.00 0.0000
3+3: MTD is higher than dose 6 0.0000
3+3: MTD is inconclusive 0.0003
Scenario 2
3+3: MTD is lower than dose 1 0.1123
1 0.6mg/kg 0.0500 0.1100 0.3520 0.2783 8.33 4.44 0.1081
2 0.8mg/kg 0.1000 0.2000 0.4564 0.4107 6.89 4.65 0.1979
3 1.2mg/kg 0.2000 0.3600 0.1813 0.1822 3.66 3.24 0.3613
4 1.8mg/kg 0.3500 0.5500 0.0102 0.0139 0.65 1.02 0.5502
5 2.7mg/kg 0.5000 0.6900 0.0001 0.0002 0.04 0.09 0.6667
6 3.6mg/kg 0.7000 0.8400 0.0000 0.0000 0.00 0.00 0.8889
3+3: MTD is higher than dose 6 0.0000
3+3: MTD is inconclusive 0.0024
Scenario 3
3+3: MTD is lower than dose 1 0.0264
1 0.6mg/kg 0.0500 0.0500 0.0496 0.0938 4.74 3.64 0.0487
2 0.8mg/kg 0.1000 0.1000 0.2615 0.2852 5.76 4.32 0.1001
3 1.2mg/kg 0.2000 0.2000 0.4869 0.3768 6.23 4.56 0.1997
4 1.8mg/kg 0.3500 0.3500 0.1860 0.1680 3.12 3.14 0.3478
5 2.7mg/kg 0.5000 0.5000 0.0160 0.0185 0.65 1.08 0.5003
6 3.6mg/kg 0.7000 0.7000 0.0000 0.0000 0.04 0.14 0.7011
3+3: MTD is higher than dose 6 0.0015
3+3: MTD is inconclusive 0.0298
Scenario 4
3+3: MTD is lower than dose 1 0.0040
1 0.6mg/kg 0.0500 0.0200 0.0031 0.0253 3.52 3.24 0.0189
2 0.8mg/kg 0.1000 0.0500 0.0523 0.0935 4.00 3.63 0.0494
3 1.2mg/kg 0.2000 0.1000 0.2858 0.2632 5.47 4.27 0.0974
4 1.8mg/kg 0.3500 0.2000 0.4246 0.3393 5.40 4.43 0.1988
5 2.7mg/kg 0.5000 0.3200 0.2241 0.1478 2.78 3.12 0.3201
6 3.6mg/kg 0.7000 0.5200 0.0101 0.0000 0.50 1.04 0.5177
3+3: MTD is higher than dose 6 0.0380
3+3: MTD is inconclusive 0.0889
Scenario 5
3+3: MTD is lower than dose 1 0.0016
1 0.6mg/kg 0.0500 0.0100 0.0003 0.0090 3.22 3.11 0.0090
2 0.8mg/kg 0.1000 0.0300 0.0139 0.0370 3.47 3.35 0.0298
3 1.2mg/kg 0.2000 0.0600 0.1145 0.1199 4.39 3.75 0.0602
4 1.8mg/kg 0.3500 0.1200 0.2972 0.2405 5.17 4.23 0.1172
5 2.7mg/kg 0.5000 0.2000 0.4860 0.2701 4.43 4.12 0.1972
6 3.6mg/kg 0.7000 0.3700 0.0881 0.0000 1.75 2.42 0.3733
3+3: MTD is higher than dose 6 0.2011
3+3: MTD is inconclusive 0.1208
Scenario 6
3+3: MTD is lower than dose 1 0.0010
1 0.6mg/kg 0.0500 0.0100 0.0000 0.0007 3.19 3.08 0.0098
2 0.8mg/kg 0.1000 0.0100 0.0013 0.0108 3.12 3.11 0.0079
3 1.2mg/kg 0.2000 0.0300 0.0267 0.0285 3.59 3.32 0.0297
4 1.8mg/kg 0.3500 0.0500 0.0974 0.0900 4.06 3.60 0.0509
5 2.7mg/kg 0.5000 0.1000 0.4604 0.2070 4.80 4.10 0.1013
6 3.6mg/kg 0.7000 0.2000 0.4142 0.0000 4.44 3.53 0.1980
3+3: MTD is higher than dose 6 0.6067
3+3: MTD is inconclusive 0.0553
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Table A.6: A Comparison Chart of Software Programs for CRM
dfcrm v0.2-2 bCRM v1.1.3 CRM v1.0
Background
Available on website X X X
Menu Driven X
Simulation X X X
Simulate ‘3+3’ X
Single Trial X X X
Method
CRM X X X
TITE-CRM X
Bivariate CRM X
Model
Power X X
Logistic X X X
Stopping Rule
Bayesian
Ad hoc X X
Output
Plot of Skeleton X
Plot of Posterior Prob. X
SD of Estimates X
Prob. dose selected as MTD X X
Est. post. Prob. of dose levels X X
Appendix B
GCR-CRM
B.1 Scenarios: Bin-GCR-CRM
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Figure B.1: Scenarios for Bin-GCR-CRM
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